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Venous thromboembolism (VTE) is a collective term for pulmonary embolism (PE) and deep vein 
thrombosis (DVT). Chronic Obstructive Pulmonary Disease (COPD) is described as a moderate risk 
factor for VTE, but the association has so far been scarcely examined. The aims of this thesis were to 
I) investigate the impact of COPD on the risk of incident VTE and the risk of mortality in COPD-patients 
with VTE; II) examine the impact of hypoxia and respiratory symptoms (cough, phlegm and dyspnea) 
on the risk of VTE in subjects with and without COPD; and III) investigate the impact of COPD on 
mortality risk in VTE patients. Study participants were recruited from the fifth and sixth surveys of the 
Tromsø-study conducted in 2001-02 and 2007-08, respectively. Using a cohort design, >8600 
participants were followed from the date of inclusion until 2011 (paper I) or 2016 (Paper II) and all 
VTEs occurring during follow-up were recorded. Information on mortality was derived from the 
national population registry.  
 We found no linear increase in the risk of VTE across stages of COPD. However, there was a 
threshold effect, where patients with severe COPD (stage III/IV) had a 1.6 fold higher risk of overall 
VTE, and a 2-fold higher risk of secondary VTE, compared to subjects without COPD. VTE was also a 
strong predictor of all-cause mortality in all stages of COPD. Both lowered oxygen saturation and 
respiratory symptoms were associated with an increased risk of VTE, and the combination of COPD 
and respiratory impairments yielded an additive increase in the VTE risk.  In patients with VTE, 
concomitant COPD was associated with a 2-fold higher risk of mortality, and the risk of death increased 
with the severity of COPD.  
Our findings suggest that both severe COPD, lowered oxygen saturation and respiratory 
symptoms are associated with incident VTE. Moreover, our studies showed that VTE in combination 





Venøs tromboembolisme (VTE) er et samlebegrep for lungeemboli (LE) og dyp venetrombose (DVT). 
Kronisk Obstruktiv Lungesykdom (KOLS) er beskrevet som en moderat risikofaktor for VTE, men få 
studier har undersøkt denne sammenhengen i en prospektiv kohortdesign. Formålet med dette 
arbeidet var derfor å I) undersøke om KOLS påvirker risikoen for førstegangs VTE i en generell 
befolkning, samt undersøke mortaliteten hos KOLS-pasienter med og uten VTE; II) undersøke hvordan 
oksygenmetning og respirasjonssymptomer (hoste, slim og tung pust) påvirker risikoen for VTE; og III) 
undersøke betydningen av KOLS for risiko for død hos VTE pasienter. Studiepopulasjonen besto av 
deltakere fra den femte og sjette Tromsøundersøkelsen, gjennomført i henholdsvis 2001-02 og 2007-
08. Deltakerne ble fulgt fra inklusjon i studien og fram til 2011 (artikkel I) eller 2016 (artikkel II), og alle 
VTE hendelser som oppstod i løpet av oppfølgingstiden ble registrert. Informasjon om død ble hentet 
fra folkeregisteret. 
Vi fant ingen lineær sammenheng mellom økende stadier av KOLS og risiko for VTE.  Derimot 
fant vi at pasienter med alvorlig KOLS (stadium III/IV) hadde 1.6 ganger økt risiko for total VTE, og 2 
ganger økt risiko for sekundær VTE, sammenlignet med personer uten KOLS. VTE var assosiert med økt 
risiko for død i alle stadier av KOLS. Lav oksygenmetning og respirasjonssymptomer ga økt risiko for 
VTE, og hos KOLS-pasienter bidro disse faktorene til å øke VTE risikoen ytterligere. VTE pasienter med 
KOLS hadde dobbelt så høy risiko for å dø sammenlignet med VTE pasienter uten KOLS, og risikoen for 
død økte med alvorlighetsgraden av KOLS.  
Våre funn tyder på at alvorlig KOLS, lav oksygenmetning og respirasjonssymptomer er 
forbundet med økt risiko for førstegangs VTE. Videre viste vi at VTE i kombinasjon med KOLS er 
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1.1 Epidemiology of venous thrombosis 
Venous thromboembolism (VTE) is a collective term for deep vein thrombosis (DVT) and pulmonary 
embolism (PE). DVT is the formation of a blood clot in a deep vein, mainly in the lower limbs, causing 
a partly or total obstruction of the venous flow. PE might occur as a consequence to DVT, when a part 
of the thrombus dislodges and follows the bloodstream to the lung where it obstructs the pulmonary 
circulation. However, a concomitant DVT is only found in about half of all PE patients (2-4). Total 
embolization of the thrombus, de novo formation of the thrombus in the lung or thrombus-formation 
in the right atrium of the heart because of atrial fibrillation (AF), have been launched as theories to 
explain the occurrence of PE without a concomitant DVT. AF is associated with higher risk of PE than 
DVT, and explained 20% of PE events in the Tromsø study (5).  
VTE is the third most common cardiovascular disease, causing significant morbidity and 
mortality (6). The estimated annual incidence rate is 1-2 per 1000 person-years (7-12). Several studies 
have suggested increased incidence of VTE over the last decades in various populations (13-15). Data 
from the Tromsø Study reported a 27% overall age-adjusted increase in the VTE incidence from 1996 
to 2012, from 1.6 per 1000 person-years in 1996 to 2.0 per 1000 person years in 2011, mainly caused 
by an increased incidence of PE with and without concurrent DVT (13). The increased incidence can be 
explained by both increased awareness of VTE and improved diagnostic tools (16, 17).  
The incident rate increases with increasing age, from one per 10 000 person-years in young 
adults, to one per 100 person-years in the elderly (18, 19). Women are more often affected than men 
through their childbearing years, and older men are more affected than older women (20). The 
incidence of DVT is higher (0.4-1.2 per 1000 person years) than the incidence of PE (0.3-0.8 per 1000 
person years) (6, 21).  
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Patients with a first incident VTE have a risk of recurrence of 5-7% per year, and this risk is 
more than 50 times higher than for patients without a previous VTE (11, 21-23). The cumulative 
proportion of patients with VTE recurrence is approximately 5-12% after 1 year, 12-25 % after 5 years 
and 30-40% after 10 years (5, 24-26). The risk of recurrence seems to be highest the first 6-12 months 
(24, 27), and 30-40% of all VTE-patients experience a recurrent event within ten years (9, 26). Several 
factors are associated with risk of recurrence, including malignancy, increasing age, male sex, high BMI, 
and neurologic disease with leg paresis (13, 24). The highest recurrence risk is observed in patients 
with persistent provoking factors such as cancer or inherited thrombophilia (28, 29). Patients with 
unprovoked incident events have a moderate to high risk of recurrence (around 11% the first year after 
treatment). The risk of recurrence among patients with provoked incident events depends on the type 
of provoking factor (5, 25). Transient risk factors (e.g., recent surgery and trauma, pregnancy, oral 
contraceptives and hormone therapy) present at the time of the VTE event are associated with lower 
risk of recurrence (12) compared to more persistent provoking factors like cancer. In patients with 
recurrence, the recurrent event tend to occur at the same location as the first event (i.e. PE-patients 
develop a new PE rather than a DVT) (30). In the California Patient Discharge Data Set, 6.4% of DVT 
patients developed a recurrence within 6 months of hospital discharge, of which 85% developed a 
second DVT (31). In the same study, 70% of PE patients admitted with recurrent VTE were diagnosed 
with a new PE. 
Post Thrombotic Syndrome (PTS) is the most common complication to DVT and develops in 25-
50% of the patients. Usually, PTS appears within 1-2 years after the thrombotic event (32, 33). PTS is a 
condition characterized by chronic pain, edema and dermatitis, and severely affected patients may 
develop venous leg ulcers (34, 35). Risk factors include obesity, female sex, varicose veins, proximal 
DVT location and recurrent DVTs (5, 33). Cancer, surgery, plaster casts or inherited thrombophilias do 
not influence the risk of PTS (36, 37). PTS may considerably impair mobility and quality of life (34), 
which may explain the association between DVT and subsequent work-related disability (38).  
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Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, but serious complication 
after acute PE. It is defined as  “precapillary pulmonary hypertension (PH) with a mean pulmonary 
arterial pressure (mPAP) ≥ 25 mmHg (as measured by right heart catheterization (RHC)) and mean 
pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg in the presence of chronic/organized flow-
limiting thrombi/emboli in the elastic pulmonary arteries after at least 3 months of effective 
anticoagulation”  (39). The condition affects 2-4% of survivors after acute PE (17, 39). CTEPH will 
increase fibrotic occlusion of the pulmonary artery leading to increased pulmonary vascular resistance, 
progressive pulmonary hypertension, and in the end, right heart failure (11, 17). The primary treatment 
of CTEPH is surgical removal of the obstructive material by pulmonary thromboendarterectomy (17, 
39).   
VTE is strongly associated with mortality (40, 41). An overall estimate indicates around five 
hundred thousand VTE-related deaths per year in Europe (42). The total number of combined deaths 
from breast cancer, AIDS, and road traffic accidents among the inhabitants of United Kingdom, equals 
only 20% of the number of deaths from VTE in the same population every year (43). A recent study 
from Arshad et al.  including 710 subjects with an incident VTE from 1994-2012, reported an all-cause 
mortality rate of 9% at 30 days and 16.6% at one year (27). These mortality rates are almost identical 
to those reported in a previous Norwegian study of 740 VTE patients recruited in the period 1995-2001 
(44).  
In two other observational studies, 5-10% of VTE-patients died within one month, and 20-30% died 
within 5 years (18, 27). The survival depends on the location of the thrombus (27, 44). Almost one-
quarter of the PE-events present as sudden death (45), and PE is associated with more than a 3-fold 
increase in 30-day mortality compared to isolated DVT (42, 44, 46, 47). However, the increased 
mortality of PE compared to DVT only persists the first three months (12, 44, 48, 49). Of note, PE is 
regarded the most common avoidable cause of death among hospitalized patients (50). 
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The mortality of VTE is highest for patients with underlying malignancy. VTE is the second 
leading cause of death in patients with cancer (51). In a study from the Dutch Cancer Registry, cancer 
patients with VTE had a 2.2-fold increased risk of mortality compared to cancer-patients without VTE 
(52). A Danish registry-based population study reported a 12% one-year survival among patients with 
cancer associated VTE and 36% one-year survival in cancer-patients without VTE (52).  
 
1.2 Pathophysiology of venous thrombosis  
Our coagulation system is maintaining a physiological 
balance between bleeding and thrombosis. Venous blood 
clots, unlike arterial blood clots, form under low shear 
stress on the surface of a largely intact endothelium (53). 
The exact mechanism is not completely  understood. A 
theory, presented by the German scientist Rudolph 
Virchow  in 1856,  described a model  (later known as 
Virchow’s triad),  consisting of three central, interacting 
elements in the pathogenesis of venous thrombosis (Figure 1)(54). The elements were stasis of the 
blood- flow, changes in the blood composition (i.e. hypercoagulability) and endothelial damage or 
dysfunction. Today we know that almost all recognized risk factors for VTE can be related to one or 
more of these key elements.  
Figure 1. Virchow’s triad illustrating the 




A DVT occurs most often in the large veins of the legs, 
more precisely in the venous valvular sinuses (55). During 
streamline flow and stasis in the lower limbs, a turbulent flow 
is created in these sinuses, leading to the formation of two 
counter-rotating vortices, one on top of the other. This flow-
pattern leads to severe hypoxia in the region of the lower 
vortex (Figure 2)(56).  
A normal endothelial surface presents natural 
anticoagulants like endothelial protein C-receptor, tissue 
factor pathway inhibitor (TFPI), thrombomodulin and 
heparin-like proteoglycans, to prevent the initiation of a clot. 
Endothelial dysfunction may be triggered by severe hypoxia. 
This results in a downregulation of the anticoagulant factors on the endothelial surface (55), promoting 
expression of prothrombotic factors like adhesion molecules (E-selectin, P-selectin), anti-fibrinolytic 
protein plasminogen activator inhibitor type 1 (PAI-1) and tissue factor (TF) (57, 58). The intra-cellular 
mechanism activated by hypoxia leads to high levels of hypoxia-inducible factor 1 (HIF-1) and early 
growth response-1 (Egr-1) pathways, which promote the described endothelial activation, and further, 
recruitment and activation of monocytes and platelets (53, 59). The flow-pattern in the sinuses prevent 
wash-out of blood, causing entrapment of blood cells, like circulating erythrocytes, leucocytes, TF-
positive extracellular vesicles (EVs) and platelets, all vulnerable to the severe hypoxia (Figure 3) (59, 
Figure 2. Schematic illustration of the 
blood flow observed around the venous 
valves of the deep veins. Oxygen tension is 
colour-coded with a gradient from red to 
blue: the darker the blue, the greater the 
hypoxia. The solid arrows illustrate blood 
flow direction with the development of 
vortexes in the venous valve pocket. 
Figure 3. The venous valvular sinus as a predilection 
site for VTE- initiation. The vortical flow pattern at 
the venous valvular sinus leads to a steep decline in 
oxygen tension. The resultant hypoxia activates the 
venous endothelium on the inner-lining of the 
adjacent valve, leading to the recruitment and 
binding of monocytes (Mct), platelets (Plt) and TF-
positive extracellular vesicles (EVs). TF from 
activated monocytes and EVs may activate the 





60). The activated endothelium binds leucocytes and TF-positive EVs to their surface by P- and E-
selectin, causing activation of the leucocytes who responds with expression of surface-bound TF. This 
multifactorial process causes the environment in the venous valve sinuses to change from anti- to pro-
coagulant with a local activating of the coagulation cascade as a consequence (53, 59).  
 
1.3  Risk factors for VTE 
VTE is a complex and multifactorial disease where the cause of the event remains unknown in 50% of 
the cases (61). All VTE-events can be classified as provoked or unprovoked based on the presence or 
absence of known risk factors that can be either acquired or inherited (62). An incident VTE usually 
requires a combination of different risk factors to occur (1). This is illustrated in the thrombosis 
potential model by Rosendaal (Figure 5), showing that the cumulative effect of several risk factors is 
needed to exceed the “Thrombosis threshold” in order to initiate a VTE.  
 
 
Figure 5. The thrombosis potential model adapted from Rosendaal (1). The green line illustrates 
inherited risk factors for VTE, here represented by factor V Leiden mutation (FVL). The black line 
represents the effect of increasing risk factors over time (like age). The brown line is the 
cumulative effect of the present, stable risk factors and transient risk factors (e.g. plaster cast 




1.3.1  Hereditary Risk factors 
There is a strong heritability for VTE indicating that genetic factors account for more than 60% of the 
variation in susceptibility to thrombosis (63, 64). The known genetic factors only explain a minor 
proportion of the VTE heritability, and only 16 single nucleotide polymorphisms (SNP’s) have been 
robustly associated with susceptibility to VTE. These known SNPs mainly affect factors involved in the 
coagulation cascade (65-67). First time overall incidence of VTE in carriers of a prothrombotic defect is 
0.8%/year compared to 0.1%/year in non-carriers (68). The different types of hereditary thrombophilia 
show considerable differences in life- time risk of VTE (69).  
There are in particular two mechanisms dominating the inherited thrombophilias: impairing natural 
anticoagulant pathways (loss-of-function) and potentiating procoagulant pathways (gain-of-function) 
(70).  
Mutations causing antithrombin (AT)-, protein C- and protein S-deficiencies, are all well-known 
loss-of-function mechanisms (70). Antithrombin mutations, found in 0.2% of the population, are 
associated with a 10- to 20-fold increased risk of VTE in heterozygous carriers (45, 71, 72). Protein C is 
an anticoagulant that inactivates activated factor V and VIII, with protein S as a co-factor in this process 
(73). The prevalence of both protein C- and S-deficiency are less than 1 % in the general population, 
and heterozygous carriers compared to non-carriers have a 10-fold increased risk of VTE (71). 
The factor V Leiden mutation is a gain-of-function mutation causing APC-resistance. It occurs 
in 4-7% of the Caucasian population and heterozygous carriers have a 2-5 fold increased risk of VTE 
(74), while homozygous carriers have a 10-80 fold increased risk of VTE (75, 76).  
The Prothrombin G20210A mutation has a prevalence of 2% in the Caucasian population, and 
is associated with a 3-fold increase in VTE risk compared to healthy non-carriers. The risk correlates to 
an increase in plasma prothrombin level (45, 77, 78). A concomitant factor V Leiden and prothrombin 
G20210A gene mutation is associated with a 20-fold increase in VTE risk compared to individuals with 
no mutations (79). 
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The non-O blood groups are present in 60-70% of the population (80). Individuals with B and 
A1 blood groups are at 1.5 to 2.0-fold higher risk of VTE compared with individuals with O and A2 blood 
groups (45, 80). Non-O bloods groups are associated with increased vWF and FVIII, but remains 
significantly associated with VTE even after adjustment for both of them (45, 70). Conversely, both 
high plasma levels of FVIII and vWF are associated with VTE risk after adjustment for ABO blood group 
(45, 70).  
During the last decade, a broad specter of susceptibility loci to complex diseases by GWAS 
studies (Genome Wide Association Studies) have been identified. In most cases, the identified risk 
alleles only explain a small percentage of the heritability of disease. For VTE the GWAS studies have 
revealed several novel single nucleotide polymorphisms (SNPs) associated with increased thrombosis 
risk (45), but they are only proven to have a minor effect of VTE risk with odds ratios (ORs) ranging 
from 1.10 to 1.35 . Besides, the clinical utility have been limited (45). Whole genome sequencing is an 
increasingly used approach to reveal genetic causes of VTE, and will probably be a major field in future 
research of VTE. 
 
1.3.2  Non-Inherited Risk factors 
Age: The incidence of VTE increases exponentially with increasing age from approximately 1 in 100 000 
in childhood to nearly 1 in 100 in individuals over 85 years. The mechanism(s) for the increased risk of 
VTE by age is not completely understood, but could be due to age-specific factors of thrombosis (i.e. 
muscle strength, venous insufficiency, frailty and institutionalized living) or risk factors that increases 
with age (immobility, cancer, co-morbidities) (44, 81-83). In The Tromsø-study, persons above 70 years 
had an 11-fold higher risk of VTE than those below 50 years (84). Similar results were found in other 
cohort-studies such as HUNT and LITE (10, 44).  
Sex:  The overall incidence of first VTE is approximately equal for both sexes, but differences 
according to sex are observed across age groups (10, 44, 84). Middle aged and elderly men have a 
higher risk of VTE than women of equal age, and some of this difference might be explained by taller 
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body height in men (6, 84), as height is recognized as risk factor for VTE (6, 85). Women of child-bearing 
age have a higher risk of VTE than men of equal age (84, 86), and this is mainly attributed to pregnancy 
and use of contraceptives (87-89).  
Obesity:  Globally, the prevalence of obesity (BMI>30 kg/m2) has nearly tripled during the last 
40 years. In 2016, more than 1.9 billion adults (> 18 years) were overweight, and 650 million were 
obese (90). In a recent paper from The Tromsø study, 17.1% of all men and 10.9% of all women 
participating had a BMI > 30 kg/m2 (91). Obesity is associated with 2-3 fold increased risk of VTE (91-
93), and the risk increases with increasing BMI (91). Data from the Tromsø study reported an increase 
in VTE risk by 30% per 1 SD increase in BMI, and all obesity measures (waist circumference (WC), hip-
circumference (HC) waist-hip ratio (WHR) and waist to height ratio (WHtR)) were related to risk of VTE 
(94). WC is the obesity measure that yielded the strongest risk estimate for VTE when using the 
established criteria for obesity measured by BMI, WC and WHR. WC also defined the highest number 
of persons at risk of VTE (95, 96). In addition, weight gain is associated with increased VTE-risk 
irrespective of the initial weight, but is particularly high in those already obese. A publication from the 
Tromsø study showed that further weight gain was associated with further increase in VTE-risk (97). 
The association between obesity and risk of VTE may be partly explained by presence of chronic low-
grade inflammation (98) and higher concentrations of plasminogen activator inhibitor, TF, fibrinogen, 
Factor VIII and von Willebrand factor in obese people, as these are all factors shown to be associated 
with VTE-risk (99). Further, central obesity may increase the intra-abdominal pressure, causing an 
impaired venous return and thereby stasis, which is a known contributor to increased risk of VTE (100).  
Body Height:  A tall stature is associated with increased risk of both first and recurrent VTE (85, 
101-103). A paper from the Tromsø study reported that the risk of a first-lifetime VTE increased by 
34% per 10-cm increase in body height. A stature above 181 cm yielded a two-fold higher VTE risk than 
a stature below 173 cm (85). The combination of a tall stature and obesity showed a synergistic effect 
with a five-fold increased risk of an incident VTE (104). The mechanisms that explain this increased 
VTE-risk remain unsettled. However, a predisposition to thrombosis in people with a tall stature may 
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involve a greater venous surface area and thereof greater risk of damage to the vessel wall caused by 
higher hydrostatic pressure during standing (105).  
Cancer:  In 1865, the French physician Armand Trousseau observed migratory 
thrombophlebitis on his own extremity. He assumed this to be an early sign of cancer, as he believed 
the thrombophlebitis to be caused by malignancy. Unfortunately he was right, and died two months 
later from gastric cancer (106). This sign (unexpected and migratory thrombophlebitis) has later been 
extended to include chronic disseminated intravascular coagulopathy associated with 
microangiopathy, verrucous endocarditis, and arterial emboli and have been named Trousseau’s 
syndrome (107). VTE is a frequent and severe complication of cancer, and the incidence of cancer-
related VTE is increasing. A study from the United Kingdom reported an increase in cancer related VTE-
rates during the period 1997-2006 from 10.3 to 19 per 1000 person-years. The same increase was not 
found in cancer-free patients. A study from North Carolina followed hospitalized cancer-patients from 
1995 to 2003 and found that the proportion of VTE increased from 3.6% to 4.6%, an increase of 28 % 
(108, 109).  About 18-20% of all VTE events occur in patients with cancer (108, 110, 111), and subjects 
with cancer are at a four- to sevenfold increased risk of VTE compared to cancer-free subjects (24, 
112). Clinical consequences of VTE, including recurrence, post-thrombotic syndrome and 
anticoagulant-related bleeding, occur more often in cancer patients (29, 113), and the risk of death 
following a VTE is threefold higher in cancer patients than in those without (51, 52). Several risk 
assessment models for VTE in cancer-patients have been developed during the years (114-118), but 
implementation into clinical use have so far been challenging due to the weak ability to predict incident 
VTE in several of the models (Khorana, Vienna, PROTECHT and CONKO)(119).   
Hospitalization (surgical and medical conditions): The average annual age-and sex-adjusted 
incidence of in-hospital VTE is more than 100–fold compared to the general population (120). 
Hospitalized- / institutionalized patients account for 20-30% of all incident VTEs (8, 121), whereas 
recently hospitalized patients (i.e. the 3-month period after discharge) account for 20-25% of all VTEs, 
indicating that the risk of VTE remains elevated for a substantial period of time after discharge (110, 
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122-124). Hospitalized medical patients account for 70-80% of all fatal PE events (125), and in the LITE-
study, surgery caused more than 40% of all provoked VTE events together with cancer (48%), 
hospitalization (52%) and major trauma (6%)(18).  Almost 10% of all deaths in hospital are related to 
PE (126). Patients visiting a trauma unit have 50% increased risk of an incident DVT in the absence of 
prophylactic treatment (127). The VTE-risk  remain high even in trauma patients receiving prophylactic 
anticoagulant treatment (128). As with cancer patients, several risk assessment models (RAM’s) have 
been developed for improved VTE prevention in hospitalized medical patients, but the models are 
limited with regards to validation and external validity (129, 130). One study suggested that the Padua 
Prediction Score had the best potential to improve stratification of the thromboembolic risk in 
hospitalized medical patients compared with usual practice (131).  
Myocardial infarction (MI): Several studies have shown an association between arterial 
cardiovascular diseases (MI and ischemic stroke) and the risk of incident VTE. A meta-analysis, 
reviewing clinical effects of anticoagulant therapy in suspected MI, showed that 4% of patients with 
MI had a symptomatic PE within two weeks after hospitalization (132). Two registry-based, population 
studies with case-control design from Denmark showed that patients with MI and other heart diseases 
had a transient increased risk of VTE (133, 134). In a prospective population-based cohort study, 
including 29506 participants, MI was associated with a 51 % increase of VTE and a 72% increased risk 
of PE. Further, MI was associated with a transient 4.8-fold increased (<6 months) risk of VTE with an 
even higher risk of PE (8.5-fold).  
Ischemic stroke: Many studies have shown an increasing incidence of DVT in stroke-patients 
as early as two days after the stroke (135-144). Asymptomatic DVTs have been found in 30-40% of 
stroke-patients (139, 140, 144), while symptomatic DVT is found in 1-10% (144-147). The incidence of 
PE varies from 1% to 13% (148-150). Studies conducted in the general population have also revealed 
that stroke patients are at a high risk of VTE, particularly during the first few months after the acute 
event (151-153). In the Tromsø Study, the cumulative incidence of VTE was 1.5% during the first 3 
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months in subjects with ischemic stroke (152). Patients with ischemic stroke had an overall 3-fold 
higher risk of VTE compared with participants without stroke. The risk was remarkably high the first 
month, with a 20-fold increased risk of VTE, and declined rapidly thereafter (152). PE following stroke 
is associated with a higher risk of death at both 30 days and one year, and a higher risk of disability at 
discharge (149). 
Immobilization: Even in healthy individuals, immobilization may cause venous stasis and 
increase the risk of VTE (154, 155). Immobilization caused by  travelling (airplane, bus, train, car) 
increases the risk of VTE almost 3-fold, and the risk is related to the duration of the travel (156).  
Immobilization increases the risk of VTE both in the community and during hospitalization (157). 
Immobilized patients in hospital have a high risk of VTE. The risk  is approximately doubled in medical 
bedridden patients although this risk may be influenced by the underlying disease (158). The risk is 
shown to be highest the first weeks of bed-rest (83). A study of patients >65 years showed that bed-
rest up to 14 days was associated with a 5-6 fold increase in risk of VTE. (159). Moreover, a meta-
analysis, with 43 observational studies of medical patients, reported a pooled odds ratio (OR) for VTE 
of more than two in immobilized patients compared to non-immobilized patients (158).   
Smoking: Whether smoking is a risk factor for VTE is debated. Many prospective studies have 
failed to show an association between smoking and risk of VTE (6, 10, 84, 160), whereas other 
observational studies have demonstrated an association (101, 161, 162). Moreover, some prospective 
studies have reported a correlation between heavy smoking only and risk of future VTE (163-165). In 
an individual level random-effect meta-analysis, including 9 prospective studies with a total of 244865 
participants and 4910 VTE events, current smoking was positively associated with a 19% increased risk 
of VTE (166). However, in stratified analyses cigarette smoking was associated with provoked (HR 1.36) 
but not unprovoked VTE (HR 1.08), indicating that provoking factors associated with smoking could 
mediate the risk. In a cause-specific analysis, Enga et al showed that the association between heavy 
smoking and VTE was no longer present when intermediate development of cancer and myocardial 
infarction was taken into account (167). 
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Infection:  Acute infection is regarded as a risk factor for incident VTE (8). A population-based 
case-control study reported that infection was associated with a 4-fold increased VTE-risk regardless 
of health-care setting, and that hospital-related infections were associated with a 12-fold increased 
risk (168). A recent case-crossover study, including VTE patients derived from the Tromsø cohort (169), 
showed that hospitalization caused by acute infection was a strong trigger of VTE (OR 24) overall, and 
also in non-immobilized patients (OR 14.6). Moreover, there was a synergistic effect between infection 
and immobilization on the VTE risk (169).  
 
1.4 COPD and risk of VTE 
 
1.4.1 COPD  
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) definition of Chronic obstructive 
Pulmonary Disease (COPD) states that: “COPD is a common preventable and treatable disease, is 
characterized by persistent airflow limitation that is usually progressive and associated with an 
enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. 
Exacerbations and comorbidities contribute to the overall severity in individual patients.” (170).   
COPD is characterized by an airflow limitation (obstruction) during expiration that is not fully 
reversible. This airflow limitation is associated with an inflammatory process (171). The risk for COPD 
is related to an interaction between genetic factors and different environmental exposures. The best 
known genetic risk factor is a deficiency of the serine protease α1-antitrypsin. Among the clinical risk 
factors are tobacco smoke, occupational exposure, indoor and outdoor air pollutants and infections 
considered the most important (172). The pathological process results in an accumulation of 
inflammatory mucous exudates in the small airway lumen, infiltration of the airway walls by 
inflammatory cells, and deposition of connective tissue in the airway wall. The repair-process thickens 
the airway walls and reduces the luminal volume (173, 174). The final result is a physiological shunt 
and a ventilation/perfusion (V/Q) mismatch with secondary hypercapnia (high pCO2) and hypoxemia 
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(low pO2) (175). The disease is further associated with systemic inflammation and related to co-
morbidities such as muscle dysfunction, secondary polycythemia, pulmonary hypertension, coronary 
artery disease and stroke (176-178).  
 
1.4.2 Diagnostics and staging of COPD 
FVC (Forced Vital Capacity) is the maximal volume (in liter) of air exhaled with maximally forced effort 
from a maximal inspiration (179). FEV1 (Forced Expiratory Volume in 1 second) is the maximal volume 
of air exhaled in the first second of a forced expiration following a full inspiration (179). Once 
measured, this value is compared to a predicted FEV1, calculated for a normal subject with the same 
age, height and weight (i.e. a patient’s expiratory volume is compared to the expected expiratory 
volume). FEV1% is the fraction of air in your lungs expired in one second (FEV1/FVC x 100%). This 
formula is used to determine the absence or presence of an airway-obstruction, whereas the actual 
FEV1 compared to the predicted FEV1 is used to establish the stage of COPD according to GOLD 
guidelines.   
Until 2011, the diagnosis and 
staging of COPD was based on spirometry 
alone, according to GOLD-guidelines (180). 
A post-bronkodilator FEV1<80 % in 
combination with FEV1/FVC<70%, 
indicated an obstruction in airflow 
expiration. COPD-stages I-IV were 
determined according to predefined cut-
offs of the FEV1-measured/FEV1-predicted 
fraction x 100% [Stage I >80%, Stage II 50-
80%, Stage III 30-50 % and Stage IV <30 %] (180). The diagnostic criteria were revised in 2011 with an 
assessment and management scheme that would mirror the clinical situation better (170, 181). This 
Figure 5: Global Strategy for Diagnosis, Management and 
Prevention of COPD 2013. Spirometric classification: GOLD 1-2 = 
stage I and II; GOLD 3-4 = stage III and IV in the former 
classification system. Exacerbations per year: less or equal to 1 or 
more or equal to 2. Symptoms: scoring-models mMCR (modified 
Medical Research Council Dyspnea Scale) and CAT (COPD 
assessment test). Figure adapted from (182) 
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system, based on spirometry, number of exacerbations per year and symptoms (Figure 5) combined 
with assessment of potential comorbidities, reflects the complexity of COPD, and gives a better 
prediction of future exacerbations (170, 182). In addition to this staging, there are several diagnostic 
procedures for decision of COPD sub-groups (emphysema, reversibility etc.) (180). 
 
1.4.3 Burden of COPD 
COPD is one of the few chronic diseases that have shown an increase in mortality and morbidity during 
the recent years, and it is estimated that COPD will be the 3rd leading cause of mortality worldwide, 
and the 5th leading source in terms of disease burden (measured as early mortality and disability-
adjusted life years), by 2020 (170). COPD is the most frequent cause of hospitalization due to disease 
in the respiratory organs (183). 
In Norway, the prevalence of COPD is high and include a total of 200 000 persons with all stages 
(184). This equals 5 - 6 % of the population > 40 years. Each year, about 15 000 persons are admitted 
to hospital due to exacerbations, and 150 000 patients consult their GP because of COPD-related 
problems (184).  
The mortality of chronic diseases in the lower airways during the period 2006-2014 were quite 
stable for both men (60-75/100 000 inhabitant) and women (40-50/100000 inhabitant) (185), and is 
explained by the large fraction of current- and former smokers in the population the last 40-50 years 
(184). Due to the decrease in prevalence of smoking in both sexes during the last 20 years, these 





1.5 COPD and VTE 
 
1.5.1 The impact of COPD on VTE 
The impact of COPD on VTE has so far been consider to be moderate (186) and mediated by 
concomitant risk factors such as immobilization, bronchial superinfection, right ventricular failure and 
venous stasis (187). The prevalence of acute PE (15–30%) in COPD patients is high, and because of the 
similar clinical presentation in both conditions, the possibility of clinical misinterpretation is high (187-
190).  
Knowledge on the association between COPD and VTE relies exclusively on results from 
registry-based studies reporting a two- to five-fold increased risk of VTE in COPD patients (191-196).  
However, in these studies, information on exposure and outcome was obtained from ICD-codes (and 
not further validated), and there was limited information on important confounders, such as obesity. 
Thus, the results from registry-based studies could be hampered by misclassification of exposure or 
outcomes, or confounding. 
 
1.5.2 Risk of mortality in COPD patients with VTE 
Hospitalization for acute COPD exacerbation is associated with 5–10% in-hospital mortality, increasing 
to >20% during the first year after hospital discharge (197, 198). In COPD patients, a concomitant VTE 
is associated with prolonged hospital stay and increased 1-year mortality (189). COPD patients often 
suffer from other comorbid conditions, which are frequently adjudicated as the primary cause of death 
in non-survivors (192, 199-201). Respiratory failure is considered to be the major cause of death in 
advanced COPD, but in mild to moderate COPD comorbidities such as cardiac disorders and 
malignancies are shown to be the leading cause of mortality (202). Currently, limited data exist on the 





1.5.3 The impact of Hypoxemia on VTE 
Hypoxia is defined as lower than normal oxygen content and pressure in the cell. The term hypoxemia 
refers to low oxygen content in the blood. In patients with COPD, alveolar hypoxia and subsequent 
hypoxemia increased with the severity of the disease (203), and may be present during exercise, rest 
or sleep. The prevalence of hypoxemia in COPD-patients remains somewhat uncertain, but severe 
hypoxemia appears to be relatively uncommon in large general COPD populations. A registry-based 
study of 632 COPD patients from primary care practices reported a prevalence close to 1% (204). In 
the UPLIFT trial, an RCT of 5993 COPD patients, 2% of the participants were prescribed supplemental 
oxygen (205). Conversely, more than 80% of patients with advanced emphysema, enrolled in a 
prospective randomized trial of lung volume reduction surgery (National Emphysema Treatment Trial, 
n=609), used some form of oxygen therapy during rest, exercise or sleep (206).  
It has been suggested that hypoxia can lead to a hypercoagulable state. An experimental study 
investigating this hypothesis in 20 healthy males, found a 2- to 8-fold increase in markers of coagulation 
activation when the participants were exposed to an immediate hypoxic, hypobaric environment 
similar to an airplane cabin (207). Later, equally designed experiments could not confirm these findings 
(208-210). Long haul air travel has been identified as a trigger for VTE, and the risk increases with 
increased flight duration (211-213). However, to what extent this increased risk could be explained by 
concomitant immobility has not been sufficiently investigated. An observational study investigating 
the separate effects of immobilization and hypoxia in 59 men and women, did not find any activation 
of the coagulation system, assessed by F1+2, TAT and D-dimer during any of the protocols (214).  
Coagulation activation secondary to short hypoxic exposure, has been examined in 
mountaineers with diverging conclusions (215-218). During a 3 week expedition in the Himalayas, 
healthy mountaineers, randomized into two groups with different acclimatization protocols (9 vs. 13 
days), climbed the Muztagh Ata in China (7549 m). Extended exposure to hypobaric hypoxia induced 
an activation of coagulation were D-Dimer concentrations, PT and APC-resistance exhibited 
procoagulant changes. Increased rapidity of ascent (9 vs. 13 days), was associated with ADAMTS 13 
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activity and Ristocetin Cofactor activity (219). However, none of these changes were related to clinical 
signs of VTE. Moreover, persons living at 4000-6500 m with prolonged exposure to hypoxia are 
assumed to have some degree of coagulation activation, and may have increased risk of spontaneous 
vascular thrombosis.  In support of this concept, a higher proportion of hospital admissions for 
thrombosis-related diseases from high-altitude areas (2.7%) than non-high altitude areas (0.1%) (OR: 
30.5) was reported in a population living in Haryana India (220-222).  
In a single-blind, placebo controlled study, the effect of hypoxia was examined in 20 clinically 
stable COPD-patients, randomized to either medical air (21% O2) or hypoxic air (15% O2) for 2h. A 
significant increase in TAT, F1+2 and IL-6 was found (223). The subjects in this study also had a high 
baseline of TAT and F1+2, interpreted as the pro-coagulant effect of COPD. An acute exacerbation in a 
COPD patient worsens the hypoxia (224) and increases the inflammatory response (225). Patients may 
therefore be at particularly increased risk of VTE during a COPD exacerbation. Earlier studies support 
this assumption by showing that pulmonary embolism frequently occurs in patients with an acute 
COPD exacerbation (187, 226).  
Whether oxygen saturation level is associated with risk of VTE is scarcely studied. Moreover, 
the combined effects of COPD and hypoxia has not been assessed in previous studies. 
 
1.5.4  The impact of Respiratory Symptoms on VTE 
Common COPD symptoms include dyspnea, chronic cough, sputum production, wheezing, and chest 
tightness. The symptoms are heterogeneous and vary among patients and across stages of disease 
severity (ref GOLD). Only one previous study have prospectively explored the association between 
respiratory symptoms (e.g. cough, phlegm, and dyspnea) and VTE. Kubota et al. showed that any 
respiratory symptoms were associated with increased risk of VTE, regardless of the presence of 
pathological spirometry results (227). Respiratory symptoms are not considered to constitute a causal 
factor for VTE, but are rather markers of comorbid conditions associated with VTE risk.  
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1.6 COPD-related conditions and VTE 
COPD is associated with many diseases and conditions that can influence the VTE risk.  
A nested case-control study, including 35772 patients showed increased risk for cardiac arrhythmias, 
myocardial infarction and stroke in patients with COPD (191). Several studies have shown an 
association between MI and stroke and the risk of incident VTE (132-134, 228). Moreover, chronic 
heart failure is present in 20% of COPD patients (229), and studies have shown increased risk of VTE in 
patients with heart failure (230-232). 
Cancer is strongly associated with VTE, but the risk varies by cancer site with pancreatic cancer, 
mesotheliomas and lung-cancer as the top three (108). Cancer is prevalent in COPD patients, and a 
study reported that the incidence of lung cancer in a cohort of COPD patients was 4-fold higher 
compared to the general population (233).  
In subjects without pulmonary diseases, the frequency of lower respiratory infections are 
relatively low (234). In COPD patients, lower respiratory tract infections are frequent, and constitute a 
significant comorbidity linked to the occurrence of exacerbations (235). Acute infections are also 
associated with increased risk of VTE in both hospitalized and non- hospitalized patients (168, 236), 
and the risk of VTE is particularly increased in patients with respiratory infections (169). 
A study describing obesity in COPD patients reported that 32% of the patients were 
overweight, while 38% were obese (237). Obesity is associated with 2-3 fold increased risk of VTE (91-
93), and the risk increases with increasing BMI (91).  
COPD, and particularly severe COPD, is associated with an inactive lifestyle (238, 239), and 
inactivity has been associated with increased risk of VTE (240, 241). Moreover, during acute 
exacerbation patients are generally considered to be at moderate risk for the development of VTE 
because of concomitant risk factors (187) such as immobilization (242, 243).  
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2.  Aims of the thesis 
 
• To investigate the association between stages of COPD and future risk of incident VTE in a 
population-based cohort. 
• To assess the risk of mortality in COPD patients with and without VTE. 
• To investigate whether measures of respiratory impairments, such as (i) respiratory symptoms 
and (ii) oxygen saturation (SpO2), individually and combined with COPD were associated with 
increased risk of VTE.   
• To investigate whether severity of COPD influenced mortality after a first episode of VTE when 






3.1 Study population 
The Tromsø study is a single center, population-based, cohort that has been ongoing since 1974. The 
primary aim of the study was to explore the high mortality and morbidity of cardiovascular disease in 
the male population of Northern Norway (244). With time, the study have expanded both in number 
of participants and in specter of diseases, and it is the most comprehensive population study in Norway 
during the last 40 years. Thus far, seven surveys, all following the same design, have been conducted. 
In total, more than 45 000 inhabitants of Tromsø have participated in one or more of the surveys. The 
study is managed by the Department of Community Medicine at the Arctic University of Norway, 
Tromsø.  
The three papers included in this thesis are based on data from the 5th and 6th surveys, where 
a total of 30115 persons were invited. For Tromsø 5 (conducted in 2001- 02), 76 % of the men and 81% 
of the women participated, whereas 68 % of the men and 63 % of the women participated in Tromsø 
6 (conducted in 2007-08). In both surveys, there was a second more extensive screening visit focusing 
on specified analysis like bone density, pain sensitivity, carotid ultrasound and spirometry. To these 
second visits, those who had participated in the second visit of a previous survey and a random sample 
of other participants were invited (refs). In Tromsø 5, 5939 persons (85% of those invited) participated 
in the second visit, and the corresponding number for Tromsø 6 was 7307 persons (92 % of those 
invited) (245).  
The participants were followed from enrolment in Tromsø 5 (2001-02) or Tromsø 6 (2007-08) 
until end of follow-up as specified in the different papers (December 31, 2011 in paper I, and December 






3.2 Baseline measurements 
Baseline information was collected by physical examination, blood samples and self-administrated 
questionnaires. Blood pressure was recorded with a semi-automatic device (Dinamap Vital Signs 
Monitor 1846; Critikon Ink., Tampa, Fl, USA), and three measurements were performed on the right 
arm after two minutes at rest in a sitting position. The average of the two last readings was used in the 
analyses. Height and weight were measured in subjects wearing light clothes and no shoes. BMI was 
calculated as weight in kg divided by height in meters squared (kg/m2). Non-fasting blood samples 
were collected from an antecubital vein and analyzed at the Department of Clinical Biochemistry, 
University Hospital of North Norway. The self-administered questionnaire provided information about 
education level, physical activity, alcohol consumption and smoking habits (never/former/current, 
number of cigarettes pr. day and duration in years). Information of co-morbidity and medication was 
obtained from the questionnaires (244). Cancer diagnoses prior to baseline were obtained from the 
Cancer Registry of Norway. 
 
3.3 Exposure assessment 
 
3.3.1 Identification of COPD patients  
Spirometry was carried out using a SensorMedics Vmax™ Legacy 20® (VIASYS Healthcare Respiratory 
Technologies, Yorba Linda, CA, USA) in Tromsø 5, and the Vmax Encore 20® (VIASYS Healthcare 
Respiratory Technologies) in Tromsø 6. The American Lung Association criteria for spirometry testing 
were followed (179) to assess the presence of COPD and to categorize stages of COPD in our 
population. A spirometry test was approved as acceptable in subjects who expired for more than 3 
seconds. Current drug therapy was not interrupted before the spirometry test, and a reversibility test 
was not performed (246, 247). Predicted values of forced expiratory volume in 1 second (FEV1), forced 
vital capacity (FVC) and FEV1/FVC (FEV1%) were calculated according to Langhammer et al. (248). The 




Chronic Obstructive Lung Disease (GOLD) guidelines (249, 250). Due to few subjects with severe 
obstruction, participants with COPD stages III and IV (FEV1/FVC ratio <0.7 combined with a FEV1<50% 
normal) were merged into one category for the analyses.  
The use of different spirometers in longitudinal studies may introduce bias. As the change in 
spirometers caused an increase in FEV1 of 2.5% and FVC of 5.2 % from Tromsø 5 to 6 survey, we 
adjusted the Tromsø 5 levels to accord with the Tromsø 6 levels (251). 
 
3.3.2 Measurement of oxygen saturation (SpO2) 
Pulse oximetry were measured at the second visit of Tromsø 5 and 6. SpO2 values were measured with 
a digital handheld pulse oximeter (Onyx II, model 9550, Nonin Medical, Inc., Plymouth, MN, USA). The 
participants rested at least 15 minutes before the measurement. The highest of the three 
measurements was recorded. Only values between 70% and 100% were accurate to ±2 digits according 
to the manufacturer. Values <70% were regarded as invalid (252).  
 
3.3.3 Assessment of respiratory symptoms 
Information of respiratory symptoms were obtained from a self-administered questionnaire asking 
about dyspnea in various situations, daily cough for periods of the year, chronic cough (i.e. cough with 
continuous duration more than 3 months during the last two years), and productive cough (i.e. phlegm) 
for periods of the year. Categories of dyspnea were “none”, “dypsnea when walking calmly of flat, or 
when washing and dressing” and “dyspnea at rest”. Cough was categorized into “none”, “daily cough 
for periods of the year” and “chronic cough for periods of the year”. Phlegm was categorized as “none” 
and “productive cough for periods of the year”. 
 
3.4 Outcome assessment 
All first lifetime VTE events during follow-up were identified by searching the hospital discharge 




Hospital of North Norway. It is the only hospital in the region and withholds all relevant diagnostic 
patient-information concerning radiology, outpatient consultations and hospitalizations.  
A VTE event was classified as either DVT or PE. When DVT and PE occurred at the same time, the 
event was classified as PE. The relevant discharge codes were International Classification of Diseases 
(ICD) 9th Revision codes 325, 415.1, 451, 452, 453, 671.3, 671.4, 671.9 from 1994 to 1998, and ICD 
10th Revision codes I26, I80, I81, I82, I67.6, O22.3, O22.5, O87.1, O87.3 from 1999 to 2011.  
Trained personnel from the Department of Radiology systematically reviewed the radiology 
procedure registry. This was done in order to identify potential cases of objectively confirmed VTE-
events that may have been missed caused by coding errors in the hospital discharge diagnosis 
registry. All relevant diagnostic procedures performed were examined. An additional search through 
the autopsy diagnoses register was conducted to identify cases diagnosed with VTE that either had 
caused death or had contributed to death. These were recorded as outcomes when the autopsy 
record indicated VTE as a cause of death or as a significant condition contributing to death. 
Medical records for potentially VTE cases were reviewed by trained personnel, blinded with 
regard to baseline variables. Events identified by the hospital discharge diagnosis registry or the 
radiology procedure registry were verified and recorded as a validated outcome when all four of the 
following criteria were met : (1) objectively confirmed by diagnostic procedures (compression 
ultrasonography, venography, spiral computed tomography (CT), perfusion-ventilation scan, 
pulmonary angiography or autopsy), (2) the medical record indicated that a physician had made a 
diagnosis of DVT or PE, (3) signs and symptoms consistent of DVT or PE were present, and (4) the 
patient underwent treatment with anticoagulants (warfarin, heparin or similar agents), thrombolytic 
or vascular surgery unless contraindications were specified in the medial record.  
The VTE events were further classified as provoked or unprovoked based on the presence of 
provoking factors at the same time of diagnosis. An event was defined as provoked in the presence of 
one of the following: surgery or trauma within the previous 8 weeks, acute medical conditions (acute 




more than 3 days, wheelchair use or long distance air travel over 5 hours within the last 14 days prior 
to event). In absence of these factors, the event was classified as unprovoked. 
 
3.5  Statistical analyses 
In papers I and II, person-years of follow-up were accrued for each participant from the date of 
enrollment to the date a VTE was diagnosed, the date the participant died or officially moved from the 
municipality of Tromsø, or to the end of the study period. We used a time-varying approach, which 
allowed participants who were re-measured in Tromsø 6 to update their exposure status over time. In 
paper III, person-years of follow-up were accrued from the date of the first VTE until the date of death 
or end of the study period. 
Statistical analyses were performed with STATA version 13.0 (Stata Corporation, College 
Station, TX, USA). Cox-proportional hazards regression models were used to estimate hazard ratios 
(HR) for different outcomes (incident VTE or all-cause mortality) with 95% confidence intervals (CI) 
according to the different exposures (stages of COPD, oxygen saturation or respiratory symptoms). Age 
was used as time-scale in all three papers. HRs were estimated in a sex-adjusted models and 
multivariable-adjusted models taking potential confounders such as BMI, current smoking, cancer and 
history of cardiovascular diseases into account. In some of the papers we also performed separate 
analyses for PE and DVT, as well as provoked and unprovoked VTE. Sub-distribution hazard ratios (SHR), 
taking competing risk of death into account according to the model described by Fine and Gray (253), 
were estimated in paper I. The proportional hazard assumption was tested using Schoenfeld residuals. 
4.  Main results 
 
4.1  Paper I 





The association between chronic obstructive pulmonary disease (COPD) and risk of venous 
thromboembolism (VTE) has been scarcely studied in the general population. We aimed to investigate 
the association between COPD and risk of VTE and mortality in a population-based cohort. Spirometry 
was conducted in 8646 males and females, participating in the fifth (2001-02) and sixth (2007-08) 
surveys of the Tromsø Study. Incident VTE events during follow-up were registered until December 31, 
2011. Cox-regression models with COPD stages and confounders as time varying covariates were used. 
Hazard Ratios (HR) with 95% confidence intervals for VTE and all-cause mortality were calculated. 
During a median follow-up of 6.2 years, 215 subjects developed VTE. Patients with COPD stage III/IV 
had a 1.6-fold higher risk of VTE (HR 1.61, 95% CI 0.90-2.93), two-fold higher risk of provoked VTE (HR 
2.05, 95% CI 1.02-4.10), and 2.3-fold higher risk of cancer-related VTE (HR 2.28, 95% CI 0.88-5.91) 
compared to subjects with normal airflow. COPD patients, particularly those with stage III/IV disease 
and VTE, had a higher mortality compared to COPD patients without VTE (50.2% versus 5.6% per year). 
Our findings suggest that patients with severe COPD may have increased risk of provoked VTE, 
suggesting that the association was dependent on the presence of provoking factors of VTE or cancer 







4.2  Paper II 
IMPACT OF RESPIRATORY SYMPTOMS AND OXYGEN SATURATION ON THE RISK 
OF INCIDENT VENOUS THROMBOEMBOLISM – THE TROMSØ STUDY 
Chronic obstructive pulmonary disease (COPD) is a moderate risk factor for venous thromboembolism 
(VTE). However, it remains to determine whether individual respiratory symptoms and lowered oxygen 
saturation (SpO2), individually and in combination with COPD, affect the risk of VTE. We wanted to 
investigate whether measures of respiratory impairments including (i) respiratory symptoms and (ii) 
oxygen saturation both individually and combined with COPD were associated with an increased risk 
of VTE. Exposure information (spirometry, SpO2, and self-reported respiratory symptoms) was 
collected in 8686 participants from the fifth (2001/02) and sixth (2007/08) surveys of the Tromsø 
Study. The total number of VTE-events were registered from the date of inclusion to December 31, 
2016. Cox-regression models with exposures and confounders as time varying co-variates were used 
to estimate hazard ratios (HR) with 95% confidence intervals (CI) for VTE. During 9.1 years of median 
follow-up there was 330 participants with incident VTE. Subjects with SpO2 ≤96% (lowest 20th 
percentile) had a 1.5-fold higher risk of VTE (adjusted HR 1.48, 95% CI: 1.13-1.93) compared with those 
with SpO2 ≥98%. Severe respiratory symptoms (dyspnea, cough and phlegm) were associated with a 
1.4 to 2.0-fold higher risk of VTE compared with no such symptoms. COPD, combined with respiratory 
symptoms or lowered SpO2, had an additive effect on the VTE risk. We concluded that lowered oxygen 
saturation and severe respiratory symptoms were associated with increased VTE risk. There was an 
additive effect on the risk of VTE for the combination of COPD and measures of respiratory 
impairments.  These findings suggest that particular attention with regard to preventive strategies 






4.3  Paper III 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND RISK OF MORTALITY IN 
PATIENTS WITH VENOUS THROMBOEMBOLISM – THE TROMSØ STUDY 
Previous studies have shown increased mortality in VTE patients with chronic obstructive pulmonary 
disease (COPD). It remains unknown whether this association increases with increasing stages of COPD 
or is confounded by physical inactivity. The aim of the present study was to investigate if increasing 
stages of COPD could influence the risk of mortality after a first episode of VTE when physical inactivity 
was taken into account. Patients with a first lifetime VTE (n=256) during the period 2001-2015 were 
recruited among individuals who participated and performed spirometry in the fifth and sixth surveys 
of the Tromsø Study (n=9577), a cohort derived from the general population of Tromsø, Norway. There 
were 123 deaths among the VTE patients during 2.9 years (range 1 day to 13.9 years) of follow-up 
(mortality rate 11.9, 95% CI 10.0-14.2 per 100 person-years). The risk of death was 2-fold higher in 
COPD patients compared to those with normal airflow (HR 2.01, 95% CI 1.30-3.08) after multivariable 
adjustment. We found that risk of death increased with the severity of COPD. VTE patients with COPD 
stage III/IV had a 5-fold increased risk of death (HR 5.20, 95% CI 2.65-10.2) compared to those without 
COPD, and among these patients 50% died within 3.5 months after the incident VTE event. Adjustment 
for physical inactivity had minor effect on the risk estimates.   VTE patients with COPD, and particularly 
those with severe COPD, had an increased risk of death. The adverse effect of COPD on mortality in 
VTE patients was not explained by physical inactivity among patients with COPD.  Our findings may 
suggest that particular attention should be drawn to prevention and management of VTE in patients 





5.  General discussion 
5.1  Methodological considerations  
 
5.1.1 Study Design 
All three papers are based on data from the Tromsø study, a prospective population-based cohort 
study (244). In a cohort study, a predefined population (i.e. a cohort of people) is followed from the 
date of inclusion in the study until an outcome of interest occurs, or until migration, death or end of 
the follow-up period. Compared to other designs, cohort studies have several advantages. There is a 
clear temporal sequence between exposure and outcome, which eliminates the risk of reverse 
causality. Further, compared to a retrospective study, a cohort is more likely to obtain valid and 
unbiased information on exposure status, and both absolute and relative risks may be provided (254-
256). Our cohort comprises a large number of participants, with participation rates ranging from 66-
77 % of the eligible population. This enhances the external validity and generalization of study findings 
to the background population. A disadvantage of the cohort design is the lack of ability to study rare 
diseases. A very large study population and long follow-up is required to generate results with 
adequate statistical power when the incidence of a disease is low (254-256).  
 
5.1.2 Confounding 
Confounding is present when a non-causal association between an exposure and an outcome is 
observed as a result of the influence of a third variable. A confounder is a)  causally or non-causally 
associated with the exposure, b) causally associated with the outcome, and c) not an intermediate 
variable in the causal pathway between the exposure and the outcome (257). A counfounder may 
strengthen, weaken or even inverse the direction of the observed association (257). In a randomized 
controlled trial, randomization will minimize confounding, whereas in observational studies, we seek 
to reduce confounding through statistical modelling, such as stratification and multivariable 




studies, as large within-strata variations, poor assessment of the confounding variable, and the 
presence of unmeasured or unrecognized confounders may lead to a phenomenon called residual 
confounding (278). 
Many disease exposures and outcomes are related to age. Thus, age is often an important 
confounder in medical research. Different stages of COPD have been found to be associated with 
increasing age (258), and there is a steep increase is the incidence of VTE by increasing age (44, 84). 
Thus, it is likely to assume that an apparent association between COPD stages and VTE risk could be 
explained by age. In papers I-III, we used the subjects´ age as the time-scale in the Cox-regression 
model, with the baseline age as entry-time and the age at outcome or censoring event as exit time 
(259). Thereby, the risk of VTE is compared in subjects with the same age instead of the same follow-
up time.  Hence, age is taken into account without a need for modelling its effect, with a subsequent 
more effective adjustment for age (259). 
Smoking may potentially be a confounder for the relationship between COPD and VTE. COPD 
is mainly caused by smoking (260), and nearly 50% of patients with stage IV disease in paper I smoked 
daily compared to 18% among those without COPD. Smoking has been shown to be a moderate risk 
factor for provoked VTE (167), indicating that the apparent association between smoking and VTE is 
probably due to an indirect effect on smoking-related diseases (e.g. cancer and cardiovascular 
diseases) with great impact on VTE (167).  To ensure that smoking did not confound the relationship 
between COPD and VTE, we adjusted for current smoking in paper I. 
As described in the introduction of this thesis, co-morbidities are often present in COPD (CVD, 
cancer, diabetes), and are often associated with the severity of COPD (178). Many of these co-
morbidities, particularly cancer are associated with increased risk of VTE. To account for this potential 







Bias (systematic error) refers to incorrect assessment of the association between an exposure and an 
effect in the target population that does not equal the true value (261). Bias leads to lack of internal 
validity. Bias must be distinguished from variability (random error). Variability can be diminished by 
increasing the study size (i.e. increases the precision), whereas this is not the case with bias.  
Bias cannot be undone once your data have been collected, and attempts to avoid or reduce bias are 
therefore important to consider when planning a study. There are several classifications of bias, but 
the two most “important” ones are selection bias and information bias (261). 
 
5.1.3.1 Selection bias 
Selection bias is a systematic error that occurs when the enrollment of individuals in a study results in 
a biased association between the exposure and the outcome. Selection bias is generally not a big 
problem when measuring relative effects of exposures in cohort studies. This is because both exposed 
and unexposed individuals are selected to the study before the occurrence of the outcome. However, 
selection bias can be a problem for assessing absolute risks, particularly if those who attend the cohort 
are less likely to develop the outcome than those who do not respond to the invitation.  To the Tromsø 
study surveys, participants were recruited by a written invitation and a questionnaire that had to be 
answered. The attendance rates ranged between 66% and 77 % in the Tromsø 4-6 surveys (245), which 
is considered high, and strengthens the external validity. However, there was some degree of self-
selection, especially in the very young and older age groups, which could result in a non-responder 
bias in these age groups (261). From former health studies we know that the participants tend to be 
healthier and have higher education (244). However, as we mainly performed etiological studies with 






5.1.3.2 Regression dilution bias 
All papers included in this thesis investigated modifiable risk factors, that is, risk factors which are 
prone to change over time. In prospective studies with long follow-up after measurements, it is likely 
that exposure status and risk factor profiles changes from study entry to the end of the study. Such 
changes over time may lead to a phenomenon called regression dilution bias, which often results in an 
underestimation of the true associations and type II errors (262). In this project, spirometry data and 
information on respiratory symptoms and covariates were collected at inclusion in Tromsø 5 (2001-
02) or in Tromsø 6 (2007-08.  As COPD is a progressive disease, it is assumed that some COPD patients 
would progress to more severe stages over time.  Likewise, respiratory symptoms are expected to vary 
over time. To address this challenge, we used time-varying analysis which allowed for update of 
exposure and covariates in participants who were re-measured in Tromsø 6 (n=2752) in papers I and 
II.  
 
5.1.3.3 Information bias and misclassification 
The internal validity (the extent to which observed findings lead to correct inferences) of a study may 
be reduced by information bias. Information bias occurs when there is imperfect definition of study 
variables or flawed data collection procedures that result in misclassification in exposure and/or 
outcome status for a significant proportion of study participants (263). In all the papers included in this 
thesis, information on several covariates such as smoking status and physical activity was collected 
from self-administered questionnaires. This form of collecting data is cost-efficient and valuable in 
large-scale cohort studies, but is a possible source of misclassification. It is well known that study 
subjects over-reports behavior consistent with a “healthy” lifestyle and do the opposite with 
“unhealthy” activity (264). However, some studies have shown that self-reporting gave a higher degree 




The diagnosis and stages of COPD were based on airflow measures obtained from spirometry 
and comparison to a calculated predicted value.  To differentiate between COPD (persistent airflow 
obstruction) and asthma (reversible airflow obstruction), it is recommended to perform a reversibility-
test (repeat spirometry 15 min after administration of broncholytica) to assess the reversibility of 
airflow obstruction (267). The reversibility test was not performed in the Tromsø study. This would 
potentially result in a higher prevalence of COPD patients, diluted with some patients with asthma in 
the study population (COPD is much more prevalent than asthma in the population). Before a 
spirometry test the patient should avoid intake of the regular medicine the same morning (268, 269), 
as most COPD patients use some degree of medication to improve their expiratory flow. Participants 
performing spirometry in the Tromsø-study were not instructed to avoid medication before the test.  
Thereby, some COPD patients may have presented with better airflow values than their actual values. 
This potential misclassification of COPD patients may have contributed to an underestimation of the 
true association between COPD and VTE risk.   
An important issue in this field is to avoid misclassification of healthy subjects as obstructive. 
Therefore, subjects were excluded from the analyses when peak expiratory flow (PEF) was below 3 x 
forced expiratory flow when 75 % of the air had been expired (PEF < (3 x FEF75)). All participants had 
to do the test three times after a strict instruction to adjust for miss-performances. As previously 
mentioned, the actual FEV1 compared to the predicted FEV1 was used to assess to establish the stage 
of disease. There are several different formulas for prediction of FEV1 (179, 270-272). We used the 
method of Langhammer et al. (248), as this method yields values that are representative for a 
Norwegian population. 
Two different spirometers were used in the Tromsø 5 and 6 surveys.  SensorMedics Vmax™ 
Legacy 20® ; VIASYS Healthcare Respiratory Technologies, Yorba Linda, CA, USA was used in Tromsø 5, 
and the Vmax Encore 20® ;VIASYS Healthcare Respiratory Technologies was used in Tromsø 6.  Use of 




change in spirometers caused an increase in FEV1 of 2.5% and FVC of 5.2 % between the Tromsø 5 and 
6 surveys. Values from Tromsø 5 were therefore adjusted to correspond to the levels of Tromsø 6 
(251).   
Misclassification arising from measurement errors may be non-differential (unrelated to 
incidence or prevalence of the outcomes) or differential (probability of misclassification differs 
according to incidence or prevalence of the outcomes). In cohort studies, exposure variables are 
usually measured prior to the development of the disease, and misclassification will generally be non-
differential as long as the outcome assessment is not influenced by the presence of exposure. In the 
Tromsø study, the personnel who identified and adjudicated the VTE events were blinded to the 
baseline measurements. 
 
5.1.4 Competing Risk of Death 
A particular selection bias is called “differential loss to follow”. Participants who die or withdraws from 
a study due to various reasons during the study period, may differ from those remaining in the study. 
This might be a problem in cohort studies if the rate of loss to follow-up is different for exposed and 
unexposed subjects. Death as a competing risk factor may lead to overestimation of cumulative 
incidences and hazards ratios. A statistical model developed by Fine and Gray (253) has been 
developed to overcome this problem. In this model, death is considered a competing event to the 
outcome, rather than a censoring event. This kind of bias is negligible in exposures with low mortality, 
but for exposures with high mortality, this has a considerable influence on the cumulative incidence. 
In our study of 8646 participants, 914 persons died during follow-up. As a consequence of a higher 
mortality rate in the COPD-group, the risk of VTE could be overestimated. Therefore, we calculated 
sub-hazard ratios taking competing risk by death into account by using the model described by Fine 




5.2 Discussion of main results 
 
5.2.1 COPD and risk of incident VTE. 
The first aim of this thesis was to investigate the association between COPD and risk of VTE in a general 
population. In paper I, we found no linear increase in the risk of VTE across stages of COPD 
(multivariable p-value for trend=0.2), but there was a threshold effect where patients with COPD stage 
III/IV had a 1.6-fold higher risk of VTE compared to those with normal (i.e. non-obstructive) airflow. 
The risk of PE in COPD patients was driven by an increased risk of secondary VTE events (a collective 
term for provoked and cancer-related VTEs), and no association was found between COPD and 
unprovoked VTE.  
Previous studies on the association between COPD and VTE risk have mainly been derived from 
registry-based studies. The data sources used in these studies have been characterize by low specificity 
of COPD diagnosis, limited information on important confounders and lack of objective outcome 
validation, which may limit the validity of these studies.  Results from the UK General Practice Research 
Database (GPRD) study (191), the US healthcare database study (192), Taiwan’s National Health 
Insurance Database (194) and the Saskatchewan database (193) showed a 2.5-fold, 2.7-fold, 3.5-fold 
and 5-fold higher risk of PE, respectively. Compared to these registry-based studies, our risk estimates 
for PE were considerably lower. The registry-based studies did not sub-divide COPD into stages, and 
therefore, it was not possible for them to investigate the association between degree of airflow 
obstruction and VTE risk. We, however, found a threshold effect at stage III/IV according to the GOLD 
criteria. Similar to the UK GPRD study (191), we also found an association, though not statistically 
significant, between severe COPD and increased risk of DVT.  
Data from clinical registries have shown that PE presents more frequently than DVT in patients 
with COPD (274) or asthma (275). Consistently, we also observed higher risk estimates for PE than for 
DVT in subjects with severe COPD. A COPD exacerbation can resemble an acute PE with regard to 




an over- or an under-diagnosis of PE. On one hand, a PE in a COPD patient could be interpreted and 
treated as an acute COPD exacerbation, and thereby lead to an underestimation of the true 
association. On the other hand, increased awareness of a high prevalence of PE in hospitalized COPD 
patients (190, 276), may lower the threshold for clinicians to impose diagnostic procedures for 
detecting PE. The presence of detection bias would lead to an overestimation of the association 
between COPD and PE, and could potentially explain the higher risk estimates for non-validated PEs 
observed in the registry-based studies (191-194) compared to our study and clinical registries (274, 
275). Detection bias could also partly explain the stronger association observed between COPD and PE 
rather than between COPD and DVT, as reported in most studies.  
The apparent association between COPD and risk of VTE could be affected by confounders. 
Smoking is the leading cause of COPD (277), and smoking has been associated with VTE risk in some 
(101, 161), but not all (6, 167), cohort studies. After adjustment for smoking, the impact of COPD on 
the risk of VTE remained unchanged in our study. Furthermore, smoking is associated with both COPD 
and cancer, and cancer is a well-established risk factor for VTE. Since the observed association between 
COPD and VTE could be mediated by a higher rate of cancer in COPD patients, we also performed 
cause-specific analyses (Of note, the results from these analyses were not presented in the final version 
of the paper). In these analyses, subjects who developed cancer were censored from the date one year 
before the cancer diagnosis (to exclude VTEs occurring in both occult and overt cancer). The risk 
estimates remained essentially similar in the cause-specific analyses indicating that the observed 
association between COPD and VTE was not solely mediated by cancer development during follow-up. 
This was further supported by the analyses restricted to (non-cancer) provoked VTE as an outcome, 
which showed that the risk was still 1.7-fold increased. 
Our finding of a relationship between the severity of COPD and risk of VTE could be 
overestimated due to a poorer prognosis of patients with severe COPD. When competing risk of death 
was taken into account, the risk estimates were slightly attenuated (from 1.6 to 1.4). We found that 




VTEs occurring in the presence of other provoking factors). COPD is associated with immobilization, 
bronchial superinfection, right ventricular failure and repeated hospitalizations, which can act as 
precipitating risk factors for VTE in COPD patients. Previous registry-based studies (191-194) have not 
been able to differentiate between VTE occurring in the absence (unprovoked VTE) or presence 
(provoked VTE) of such factors. The higher risk of provoked VTE, especially PE, suggests that the risk of 
VTE in patients with COPD was most likely caused by concomitant provoking factors such as 
immobilization for acute exacerbation of COPD or infections. In a more recent population-based cohort 
study (the ARIC study), Kubota et al (227) confirmed that COPD was associated with risk of provoked 
VTE, but reported that COPD also was associated with unprovoked VTE, and revealed a linear increase 
in VTE risk with the severity of airflow obstruction. The reason(s) for the differential findings between 
the studies are unknown, but may include a larger cohort with more VTE events in the ARIC study 
(greater power), the slightly different age distributions of the populations, and the different definitions 
of COPD.  
 
5.2.2 The impact of respiratory symptoms and oxygen saturation on the risk of incident 
VTE 
In the second paper, we investigated the impact of individual respiratory symptoms (i.e. dyspnea, 
cough and phlegm) and oxygen saturation, alone and in combination with COPD, on the VTE risk.  We 
found that subjects with SpO2 ≤ 96% (lowest 20th percentile) had a 1.5-fold higher risk of VTE than 
subjects with SpO2 ≥ 98% (highest 40th percentile). Moreover, severe manifestations of individual 
respiratory symptoms were associated with a 1.4 to 2.0-fold higher risk of VTE compared to those 
without such symptoms. COPD combined with severe respiratory symptoms or lowered SpO2 had an 
additive effect on the VTE risk.  
Several conditions could lead to lowered oxygen saturation, for instance obesity (251, 278), 
heart failure (279), COPD (203, 251), and cancers affecting the cardio-respiratory system (280). These 




for the association between oxygen saturation and VTE risk. However, after adjustment for obesity, 
history of CVD and cancer, the risk estimates for VTE by categories of SpO2 were only marginally 
affected.  Moreover, SpO2 was associated with increased risk of VTE in analyses restricted to subjects 
with non-obstructive airflow, further supporting that a skewed distribution of obesity, CVD, COPD and 
cancer between subjects with high and low oxygen saturation did not explain the apparent association 
between low oxygen saturation and VTE risk.  The underlying mechanism(s) for the relationship 
between hypoxia or hypoxemia and VTE risk are unknown. However, several lines of evidence support 
a direct effect. Hypoxia induces secretion of Weibel-Palade bodies in endothelial cells (284) which leads 
to subsequent expression at the cell surface and release of von Willebrand factor and P-selectin (285, 
286). P-selectin and vWF are factors known to be associated with VTE risk (287, 288). Furthermore, 
hypoxia increases platelet reactivity (289, 290), and has been shown to increase coagulation activation 
in some (207), but not all, studies (209). In murine models, systemic hypoxia has been shown to 
accelerate thromboembolic events through induction of the nucleotide binding domain, leucine-rich-
containing family, pyrin domain containing 3 (NLRP3) inflammasome complex (291). Severe hypoxia is 
also reported to increase the incidence and size of thrombi in the inferior vena cava stenosis model in 
mice (292).   
In COPD patients, hypoxemia is associated with a larger mean platelet volume (MPV) (293) and 
increased platelet reactivity (294). High MPV has been identified as a risk factor for VTE (295), and the 
protective effect of platelet inhibitors (e.g. aspirin) strongly suggests that platelet reactivity plays an 
important role in the pathogenesis of VTE (296). Finally, studies have reported a higher coagulation 
activation in COPD patients than their age- and sex-matched controls (297, 298), and exposure to 
short-term hypoxia further augments coagulation activation (223).  
Using data from the ARIC study, Kubota et al. (227) reported that in subjects with normal 
spirometry, presence of any respiratory symptom (dyspnea, cough and phlegm) was associated with 
1.4-fold higher VTE risk compared to those without respiratory symptoms. In our study, we extended 




individually associated with VTE risk, and that the VTE risk increased with the severity of the dyspnea 
and cough. Although the mechanism for the association between respiratory symptoms and VTE risk 
is unknown, it is obvious that these respiratory symptoms merely are markers rather than causal 
factors for the VTE risk. Respiratory symptoms may be attributed to associated comorbidities, such as 
immobility, cancer, heart failure and others, which can all contribute to the increased risk of VTE.  Still, 
the risk estimates for VTE by respiratory symptoms remained unchanged after adjustments for BMI, 
cancer, and CVD in our study.  We did not have information on concomitant heart failure, and 
adjustment for CVD may not have been sufficient to capture such potential confounding. Thus, we 
cannot rule out the possibility of residual confounding by heart failure or other unmeasured or 
unrecognized confounders.  
In agreement with previous cohort studies (227, 282), COPD was associated with a moderately 
increased risk of VTE that further increased with the severity of COPD.  Moreover, we found that the 
combination of COPD and lowered oxygen saturation had an additive effect on the VTE risk. 
Thromboprophylaxis with anticoagulants reduces the risk of VTE in hospitalized medical patients by 
45-66% (299, 300). Our findings may suggests that COPD patients with severe respiratory symptoms 
or lowered oxygen saturation should attract particular attention with regard to prevention strategies 
for VTE, particularly in high risk situations such as hospitalization for acute exacerbations or infections.   
 
5.2.3 Interrelations between COPD and VTE on mortality 
 
5.2.3.1 Impact of VTE on mortality among COPD patients 
A main aim of this thesis was to explore the relationship between COPD and VTE on all-cause mortality 
(papers I and III). In paper I, we investigated the impact of a VTE event on the risk of mortality among 
COPD patients. Even though it is well-known that COPD is associated with several comorbid conditions 
and a poor prognosis, limited knowledge exists on to which extent these diseases influences the risk 




comorbidities registered (from oncology, pulmonology, cardiology, gastroenterology, endocrinology 
and psychiatry), negatively influenced survival (301). In paper I, we found that occurrence of an 
incident VTE was associated with higher all-cause mortality in COPD patients, particularly among those 
with severe COPD. Our findings suggest that a VTE event has prognostic impact on survival in COPD 
patients, and particularly in patients with stage III/IV COPD, as a VTE was associated with an 11-fold 
increased risk of mortality in these patients.  
 
5.2.3.2 Impact of COPD on mortality among VTE patients 
In paper III, we investigated whether COPD influenced the risk of all-cause mortality in VTE patients. 
We found that VTE patients with concomitant COPD had a 2-fold higher risk of death compared to VTE 
patients without COPD, and that the mortality rates and relative risks of mortality in VTE patients 
increased with the severity of COPD. In patients with PE, those with COPD stage III/IV had a 7.3-fold 
higher risk of death compared to those without COPD. In DVT patients, the risk of death was 3.8-fold 
higher in those with COPD stage III/IV. The overall mortality risk was high in VTE patients with COPD 
stage III/IV, as 50% died within the initial 3.5 months. The higher death rate in VTE patients with severe 
COPD could not be explained by concomitant cancer, as the results remained essentially unchanged 
when cancer was adjusted for. Moreover, a higher proportion of physical inactivity did not explain the 
increased mortality risk in COPD patients.  
Our findings of a 2-fold increased mortality risk are coherent with those of previous studies. In 
a cohort of 399 PE patients, the presence of chronic lung disease (defined by a history of COPD, 
interstitial lung disease or pulmonary fibrosis on chest radiography) was associated with a 2.2-fold 
increased risk of death (302). Moreover, in a study of VTE patients derived from Olmstedt County 
residents in the period 1966-1990 (n=2218), chronic lung disease was associated with a 1.4-fold 
increased risk of both short- and long-term mortality after multivariable adjustments (48). Among 2488 
VTE patients from the Worcester study, 19.5% had a history of COPD, and concomitant COPD was 




In paper III, we additionally showed that the impact of COPD on mortality in VTE patients 
increased with the severity of COPD. VTE patients with concomitant COPD stage III/IV had a 5.3-fold 
higher mortality risk than those without COPD, and the mortality rate was particularly high during the 
first months after VTE diagnosis. Our findings indicated that approximately 60% of VTE patients with 
concomitant COPD stage III/IV will die during the first year after a VTE diagnosis. This proportion is of 
similar magnitude as the 1-year mortality in cancer-related VTE, which is reported to be around 60% 
(27, 44). 
Several mechanisms may underlie the observed impact of COPD on VTE-related mortality.  
Since COPD patients often suffer from other diseases (48, 302, 303), such as arterial cardiovascular 
diseases and cancer, presence of comorbid conditions may confound the apparent association 
between COPD and VTE-related mortality. Smoking is associated with both COPD and cancer (277, 
304), and active cancer is associated with increased risk of VTE (283) as well as a substantial worsening 
of the VTE prognosis (27, 44). Moreover, COPD is associated with arterial cardiovascular diseases (305), 
and arterial cardiovascular diseases are associated with a transient increased risk of VTE  (152, 228) 
and a poor prognosis (202). When active cancer and a history of MI and stroke were included in our 
adjustment models the risk estimates of VTE-related mortality remained essentially unchanged, 
suggesting that the impact of COPD on VTE-related mortality was neither explained by concomitant 
cancer, nor arterial cardiovascular diseases. Moreover, although severe COPD is associated with a 
sedentary behavior (238, 239, 306) and frequent immobilization during hospitalization (303), the 
impact of COPD on VTE-related death was not explained by inactivity since adjustment for inactivity 
had a minor effect on the risk estimates for death in COPD patients. Unfortunately, we did not have 
information on heart failure, and could therefore not take this into account in our analyses. Patients 
with COPD and chronic right ventricular dysfunction are susceptible to cardiovascular collapse due to 
superimposed right ventricular failure following symptomatic and asymptomatic PE (307), and this 





6.  Conclusions 
• Patients with severe COPD (stage III/IV) had increased risk of secondary VTE, including both 
provoked and cancer-related VTE, a relationship mainly driven by the risk of PE.  
• Patients with COPD and incident VTE had higher mortality rates than COPD-patients without VTE. 
• Respiratory impairments, such as lowered oxygen saturation and severe respiratory symptoms 
(dyspnea, cough and phlegm), were associated with increased VTE risk.  
• COPD combined with individual respiratory symptoms (dyspnea, cough and phlegm) or lowered 
oxygen saturation had an additive effect on the risk of VTE.   
• VTE patients with COPD had an increased risk of death compared to VTE patients without COPD, 
and the risk was particularly high in patients with severe stages of COPD. The increased risk of 
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“Take home” message 
Patients with severe COPD may have increased risk of VTE. VTE is associated with a worse 




Background: The relationship between chronic obstructive pulmonary disease (COPD) and 
risk of venous thromboembolism (VTE) has been scarcely studied in the general population.  
We aimed to investigate the association between COPD and risk of VTE and mortality in a 
population-based cohort.   
Methods: Spirometry was conducted in 8646 men and women, participating in the fifth 
(2001/02) and sixth (2007/08) surveys of the Tromsø Study. Incident VTE-events during 
follow-up were registered from the date of inclusion to December 31st, 2011. Cox-regression 
models with COPD stages and confounders as time varying co-variates were used to calculate 
hazard ratios (HR) with 95% confidence interval (CI) for VTE and all-cause mortality. 
Results: During a median follow-up of 6.2 years, 215 subjects developed VTE. Subjects with 
COPD stage III/IV had a 2-fold higher risk of secondary VTE compared to subjects with 
normal airflow (HR 2.05, 95% CI: 1.02-4.10). COPD patients, particularly those with stage 
III/IV, with VTE had a higher mortality rate than COPD patients without VTE (50.2% versus 
5.6% per year).    
Comments: Our findings suggest that patients with severe COPD may have increased risk of 
secondary VTE, and that COPD patients with VTE have a higher mortality rate than COPD 







The prevalence of chronic obstructive pulmonary disease (COPD) has increased 
dramatically in western populations during the last decades [1, 2] , and has become a major 
challenge to public health and health care systems due to frequent hospitalizations, severe co-
morbidities, and a high mortality rate [2, 3]. Venous thromboembolism (VTE), a collective 
term for deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common disease 
with complications such as the post-thrombotic syndrome, chronic thromboembolic 
pulmonary hypertension (CTEPH) and death [4, 5]. COPD is considered a moderate risk 
factor of VTE [6].  Moreover, there is a high prevalence of acute PE (15-30%) in COPD 
patients interpreted as acute exacerbations [7-10].  In COPD patients, it has been assumed that 
the risk of VTE, and PE in particular, is mediated by concomitant risk factors such as 
immobilization, bronchial superinfections, right ventricular failure and venous stasis [8].  
Knowledge on the impact of COPD on VTE risk in the general population relies 
exclusively on results from registry-based studies reporting a 2 to 5-fold increased risk of 
VTE in COPD patients [11-14]. In these studies the exposure (COPD) and outcome (VTE) 
were defined according to ICD-codes and treatment with COPD medications. Previous studies 
have reported low validity of COPD diagnoses obtained from administrative databases [15, 
16]. Similarly, a validation of VTE diagnoses in the Danish National Patient Registry reported 
positive predictive values (PPV) for VTE diagnoses from emergency departments and 
hospitals of 44% and 67-77%, respectively [17]. Thus, it is not known whether risk ratios 
presented by previous registry-based studies are valid or suffer from a high degree of 
misclassification (i.e. false positive or false negative events) or confounding due to lack of 
important clinical information such as provoking factors for VTE.  
Hospitalization for acute COPD-exacerbation is associated with 5-10% in-hospital mortality, 
increasing to more than 20% during the first year after hospital discharge [18, 19]. A 
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concomitant VTE-event is associated with prolonged hospital stay and higher 1-year mortality 
[9]. COPD patients frequently suffer from comorbidities of which often are adjudicated as the 
primary cause of death in non-survivors [12, 20]. Recently, some comorbidities were shown 
to augment the mortality rate in a cohort of 1664 COPD patients [21]. However, limited data 
exist on the prognostic impact of VTE on mortality in COPD patients recruited from a general 
population.   
We therefore set out to investigate the association between stages of COPD, according 
to the GOLD criteria [22], and future risk of secondary (presence of one or more predisposing 
factors) and unprovoked VTE in a population-based cohort with well-recorded confounder 
information and validated VTE events. Furthermore, we aimed to assess the risk of mortality 


















Study participants were recruited from the fifth (2001-02) and sixth (2007-08) surveys of the 
Tromsø Study [23]. To these surveys, parts of the population aged ≥30 years living in the 
municipality of Tromsø, Norway, were invited to participate in an extensive screening where 
spirometry was included. A detailed description of study participation has been published 
elsewhere [23]. The overall attendance rate was high with 85% (n=5918) of those invited in 
Tromsø 5, and 74% (n=7306) in Tromsø 6. A total of 9577 unique individuals aged 32-89 
years participated in at least one of the surveys, and of these, 3647 participated in both 
surveys. The regional committee of medical and health research ethics approved the study, 
and all subjects gave their written consent to participate. Subjects who were not officially 
registered as inhabitants of the municipality of Tromsø at date of study enrolment (n=12], 
subjects with VTE before baseline (n=113], and subjects with missing values for spirometry 
measures (n=806) were excluded. Accordingly, 8646 subjects were included in the study, and 




Data were collected by physical examination, blood samples and self-administrated 
questionnaires. Height and weight were measured with subjects wearing light clothes and no 
shoes, and body mass index (BMI) was calculated as weight in kilograms divided by the 
square of height in meters (kg/m2). Baseline information on current smoking, self-reported 
history of cardiovascular disease (myocardial infarction, stroke or angina) and diabetes was 
collected from the questionnaire. Non-fasting blood samples were collected from an 
antecubital vein. Serum was prepared by centrifugation after 1 h respite at room temperature, 
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and analysed at the Department of Clinical Chemistry, University Hospital of North Norway. 
Information on cancer before inclusion and during follow-up was obtained from the 
Norwegian Cancer Registry [24]. 
Calibration of the spirometer was performed every morning and on the machine 
demand. The subjects were sitting, using a nose clip, and were instructed to blow as long as 
possible and at least for 6 seconds. At least three exhalations were required. The American 
Lung Association criteria for spirometry testing were followed [25]. Current drug therapy was 
not interrupted before the test. Reversibility test was not performed. Predicted values of 
forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and FEV1/FVC 
(FEV1%) were calculated according to Langhammer et al. [26]. Spirometry was accepted in 
subjects who expired for more than 3 seconds. To avoid misclassification of healthy subjects 
as obstructive, those with FEV1/FVC <0.7 or predicted FEV1 <80% were excluded from the 
analyses if peak expiratory flow (PEF) was below 3 x forced expiratory flow when 75% of the 
air had been expired (PEF >3 x FEF75). Spirometry was carried out using a SensorMedics 
Vmax™ Legacy 20® (VIASYS Healthcare Respiratory Technologies, Yorba Linda, CA, 
USA) in Tromsø 5, and the Vmax Encore 20® (VIASYS Healthcare Respiratory 
Technologies) in Tromsø 6. Use of different spirometers in longitudinal studies may introduce 
bias [27]. The change in spirometers caused an increase in FEV1 of 2.5% and FVC of 5.2 % 
from Tromsø 5 to 6 survey [28]. Therefore, we adjusted the Tromsø 5 levels to accord with 
the Tromsø 6 levels.  
 The subjects were allocated into four groups based on lung function according to the 
Global Initiative of Chronic Obstructive Lung Disease (GOLD) guidelines [22]. Due to few 
subjects with severe obstruction, participants with COPD stages III and IV (FEV1/FVC ratio 





All incident VTE events during follow-up were identified by searching the hospital 
discharge diagnosis registry, the autopsy registry and the radiology procedure registry at the 
University Hospital of North Norway as previously described [29]. The University Hospital of 
North Norway is the only hospital in the region, and all diagnostic radiology and hospital care 
is provided exclusively by this hospital. The medical record for each potential case of VTE 
was reviewed by trained personnel, and a VTE was considered verified and recorded when 
presence of clinical signs and symptoms of DVT or PE were combined with objective 
confirmation tests (by compression ultrasonography, venography, spiral computed 
tomography, perfusion-ventilation scan, pulmonary angiography, or autopsy), and resulted in 
a VTE diagnosis that required treatment, as previously described in detail [29]. VTE cases 
derived from the autopsy registry were recorded when the death certificate indicated VTE as 
cause of death or a significant condition associated with death. The VTEs were classified as 
unprovoked or secondary depending on the presence of provoking factors at the time of 
diagnosis, and the secondary events were further classified into provoked and cancer-related 
events. Provoking factors were recent surgery or trauma within the previous 8 weeks, acute 
medical conditions (acute myocardial infarction, ischemic stroke or major infectious disease), 
immobilization (bed rest >3 days, wheelchair use or long-distance travel exceeding 4 hours 
within the last 14 days prior to the event) or other presumable provoking factor specifically 
described by a physician in the medical record (e.g. intravascular catheter). Cancer-related 
VTE was defined as VTE events occurring in patients with active cancer (i.e. patients with 
overt cancer who were under treatment or surveillance for their cancer diagnosis).  






For each participant, person-years for follow-up were accrued from the date of enrollment to 
the date a VTE was diagnosed, the date the participant died or officially moved from the 
municipality of Tromsø, or to the end of the study period (December 31st, 2011). Subjects 
who died (n=914) or moved from Tromsø (n=318) during follow-up were censored at the date 
of migration or death.  We used a time-varying analysis that allowed participants (n=2752) 
who were re-measured in Tromsø 6 to change their stage of COPD over time. Thus 8646 
individuals contributed with 11398 observational periods. This is graphically illustrated in 
Figure 1.  
Statistical analyses were performed with STATA version 13.0 (Stata corporation, 
College Station, TX, USA). The significance level was 0.05. Crude incidence rates (IR) with 
95% confidence interval (CI) were calculated and expressed as number of events per 1000 
person-years.  Cox-proportional hazards regression models, with stages of COPD and 
potential confounders entered as time-varying co-variates were used to estimate hazard ratios 
(HR) with 95% CI for VTE across stages of COPD. Age was used as time-scale, and the HRs 
were estimated in sex-adjusted analyses, and in a multivariable model including sex, BMI, 
current smoking, and history of cardiovascular disease. In addition, IRs and HRs for PE and 
DVT, as well as provoked and unprovoked VTE, were calculated separately. The proportional 
hazard assumption was tested using Schoenfeld residuals, and statistical interactions between 
COPD and sex were tested by including cross-product terms in the proportional hazards 
model. No statistical interactions between COPD and sex were found. 
Hypothetically, death may prevent the observation of a future VTE during the follow-
up period, and consequently the cause-specific HRs may overestimate the risk of VTE in 
COPD patients. Since the overall risk of mortality was expected to be different across stages 
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of COPD, we also calculated sub-hazard ratios taking competing risk of death into account by 
using the model described by Fine and Gray [30].  
Finally, Cox-regression models were applied to investigate the impact of COPD stages 
on mortality in patients without and with VTE. In these analyses, both stages of COPD and 




The distribution of baseline characteristics across stages of COPD is shown in Table 1. The 
frequency of self-reported symptoms of dyspnoea, daily cough and chest wheezing was higher 
in stage IV, as were the numbers of current smokers and pack years among both current and 
former smokers. There were no differences in the distribution of co-morbidities (cancer, CVD 
and diabetes) between the different stages. 
There were 215 validated VTEs during a median of 6.2 years of follow-up. In total, 
50.5% presented with a clinically symptomatic PE with or without concurrent DVT, whereas 
49.5% were DVTs only (Table 2). Moreover, 37.2% of the events were unprovoked. Cancer 
was the most frequent provoking factor and 30.9% of the VTE patients had a cancer-related 
VTE. 
The total follow-up time was 57190 person years, and the overall crude IR was 3.76 
per 1000 person-years (Table 3). There was no linear increase in the risk of VTE across stages 
of COPD (multivariable p for trend: 0.2). However, there was a threshold effect, and patients 
with COPD stage III/IV had a 1.6-fold higher risk of VTE compared to those without COPD 
(HR 1.61; 95% CI: 0.90-2.93). Moreover, subjects with COPD stage III/IV had a 2-fold 
higher risk of secondary VTE compared to subjects with normal airflow (HR 2.05, 95% CI: 
1.02-4.10), and similar risk estimates were found in subgroup analyses of provoked VTE (HR 
1.71; 95% CI: 0.60-4.88) and cancer-related VTE (HR 2.28; 95% CI: 0.88-5.91). The hazard 
ratio of PE in subjects with COPD stage III/IV versus normal airflow was 1.83 (95% CI: 0.83-
4.02) (Table 3).  
When competing risk of death was taken into account, the relative risk estimates were 
attenuated, but still, subjects with COPD stage III/IV had about 40% increased risk of VTE 
compared to those with normal airflow (multivariable SHR 1.39, 95% CI: 0.76-2.55) 
(Supplementary table 1).  
11 
 
The mortality rates and hazard ratios of mortality according to stages of COPD and 
VTE status are shown in Table 4. Overall, COPD patients with VTE had a 5-fold (HR 5.54, 
95% CI 4.01-7.66) higher risk of dying than those without VTE. Moreover, within the 
different stages of COPD both the absolute risks and the relative risks of mortality were 
higher in VTE patients than in patients without VTE (Table 4 and Figure 2). Patients with 
COPD stage III/IV and VTE had a mortality rate of 50.2% per year and an 11-fold (10.88, 




We have investigated the impact of COPD on risk of VTE, and the impact on VTE on all-
cause mortality in COPD patients, in a cohort recruited from the general population with 
validated exposures and outcomes. Subjects with severe COPD had a 1.6-fold higher risk of 
VTE compared to those with normal airflow. The risk of VTE, particularly PE, by COPD was 
driven by secondary events, and no association was found between COPD and unprovoked 
VTE events. However, the confidence intervals were wide, and the risk estimates derived 
from the association between COPD and VTE should therefore be interpreted with caution. 
Additionally, we found that VTE was a strong predictor of all-cause mortality in COPD 
patients, particularly among those with severe COPD. 
A few registry-based studies have previously investigated the relation between COPD 
and VTE. In general, low specificity of COPD diagnosis, limited information on important 
confounders, and lack of objective outcome validation may limit the validity of studies based 
on administrative registry data only. Our risk estimates for PE were lower than those from the 
UK General Practice Research Database (GPRD) study [11], the US health care database 
study [12], the Taiwan’s National Health Insurance Database (NHIRD) [14],  and the 
Saskatchewan database [13] which reported a 2.5-fold, 2.7-fold, 3.5-fold and 5-fold higher 
risk of PE, respectively. These studies treated COPD as a dichotomous variable and were 
therefore unable to look at the degree of airflow obstruction and risk of VTE, while we found 
a threshold effect at stage III/IV according to the GOLD-criteria. Similar to the UK GPRD 
study [11] we found that those with severe COPD had a 1.4-fold higher risk of DVT, though 
this association was not statistically significant. 
 Data from clinical registries have shown that PE presents more frequently than DVT 
in patients with COPD [31] or asthma [32]. Accordingly, we observed higher risk estimates of 
PE than DVT in subjects with severe COPD. A COPD patient with an exacerbation would 
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symptomatically resemble a patient with an acute PE, and in many cases the two conditions 
cannot be clinically distinguished. This may result in either an overdiagnosis or an 
underdiagnosis of PE. Awareness of a high prevalence of PE in hospitalized COPD patients 
among clinicians [1, 10], may entail a preponderance to impose diagnostic procedures for 
detecting this disease. Presence of detection bias would lead to an overestimation of the 
association and could potentially explain the higher risk estimates for not validated PEs 
observed in the registry-based studies [11-14] compared to our study and clinical registries 
[31,32].  Moreover, detection bias could also partly explain the strong association of COPD 
with PE rather than DVT found in most studies.  
Any association between COPD and risk of VTE may be affected by confounders.  
Smoking is the leading cause of COPD [33] and also associated with risk of VTE in some [34, 
35], but not all [36, 37], cohort studies. In our study, the impact of COPD on the risk of VTE 
remained unchanged after adjustment for smoking. Smoking is associated with both COPD 
and cancer, and cancer is a strong risk factor for VTE. Thus, the observed association between 
COPD and VTE could be confounded by a higher rate of cancer in COPD patients during 
follow-up. Using cause-specific analyses, we showed that the risk of VTE in severe COPD 
patients was not explained by cancer. Our finding of a relation between the severity of COPD 
and risk of VTE could be biased by poorer prognosis of patients with severe COPD. When 
competing risk of death was taken into account, the risk estimates were only slightly 
attenuated from 1.6 to 1.4. 
Immobilization, bronchial superinfections, right ventricular failure, and repeated 
hospitalizations have been suggested as precipitating risk-factors for VTE in COPD patients. 
Previous registry-based studies [11-14] have not been able to differentiate between VTE 
occurring in the absence (unprovoked VTE) or presence (provoked VTE) of such factors. We 
found a higher risk of provoked VTE which suggests that the risk of VTE in patients with 
14 
 
COPD was most likely caused by concomitant provoking factors such as immobilization for 
acute exacerbation of COPD or infections.   
Even though it is well known that COPD is associated with several comorbidities and 
poor prognosis, limited knowledge exist on how these diseases contribute to prediction of 
mortality in COPD patients.  Recent results from a cohort of COPD patients with 
simultaneous registration of comorbidities revealed that some of these diseases predicted 
mortality in COPD patients [21].  In our study, we found that occurrence of a VTE was 
associated with higher all-cause mortality in COPD patients, particularly among those with 
severe COPD. Our findings suggest that a VTE event has prognostic impact in COPD 
patients.   
Strengths of our study include the recruitment of subjects from the general population, 
long-term follow-up with repeated measurements of exposure and confounders, and thorough 
identification and validation of outcomes.  Measuring airflow by spirometry allowed us to 
grade an individual’s stage of COPD according to GOLD guidelines. Status on potential 
confounders was assessed each time spirometry was (re-)measured, and we adjusted for these 
in the time-dependent analyses. The cohort design ensured a clear temporal sequence between 
exposure and outcome, and that potential exposure misclassification would be non-differential 
(i.e. not related to the outcome and thereby dilute the observed effect). Some limitations merit 
consideration. The statistical power was low in some subgroups, resulting in wide confidence 
intervals. We detected a HR of 1.6 in severe COPD versus normal airflow. However, due to 
the low prevalence of severe COPD, the statistical power of this analysis was only 20% 
indicating a high chance of type II error (failure to reject a false null hypothesis). To be able 
to detect a hazard ratio of 1.6 with 80% power, we would have needed a cohort of around 
40 000 individuals. COPD exacerbations are related to hospitalization, immobilization, 
infections and other conditions that may predispose for VTE. Unfortunately, we did not have 
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detailed information on hospital-related factors during follow-up for all individuals, and could 
therefore not investigate the role of these factors with regard to VTE risk in COPD patients. 
Finally, our spirometry measures were carried out without reversibility-test. Consequently, 
some subjects with asthma may have been misclassified as having COPD. This potential 
misclassification would be non-differential, and would most likely lead to an underestimation 
of the true association due to regression dilution bias.  
In conclusion, severe COPD was associated with increased risk of secondary VTE, 
implying that the association was dependent of the presence of provoking factors of VTE or 
cancer in COPD patients. Although our results were obtained from a relatively large 
population cohort, the number of events was low in some subgroups, and the risk estimates 
for the association between COPD and VTE should therefore be interpreted with caution. 
Additionally, we found that VTE was a strong predictor of all-cause mortality among COPD 
patients. 
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Figure 1. Overview of study inclusion. A total of 8646 unique individuals were included in 
the study. Of these, 2320 individuals participated in Tromsø 5 only, 3574 participated in 
Tromsø 6 only, and 2752 participated in both surveys, resulting in 11398 observational 
periods.  
 
Figure 2. Age and sex-adjusted survival curves according to stages of chronic obstructive 




Table 1. Distribution of characteristics in 11398 observation periods (generated by 8646 
unique individuals) across stages of COPD according to Gold Guidelines. The Tromsø study 
2001-2011. 
 
 Normal COPD  Stage I 
COPD 
 Stage II 
COPD 
 Stage III/IV 
Observation periods, % 77.8 (8869) 9.2 (1051) 10.8 (1226) 2.2 (252) 
Sex (male) 41.4 (3323) 48.9 (549) 49.7 (722) 57 (156) 
Age (years) 63.0 ± 9.5 67.7 ± 9.2 67.8 ± 8.4 69.3 ± 7.6 
FEV1 (liters) 2.7 ± 0.7 2.6 ± 0,7 1.9 ± 0.5 1.1 ± 0.3 
FVC (liters) 3.6 ± 1.0 3.9 ± 1.0 3.1 ± 0.8 2.3 ± 0.7 
FEV1/FVC (%) 76.6 ± 4.0 66.4 ± 3.5 62.6 ± 6.0 49.9 ± 10.1 
FEV1 % normal 93.5±14.2 91.3±9.5 67.5±8.3 40.2±8.4 
Dyspnea,§ % 2.8 (146) 3.9 (31) 5.9 (61) 19.5 (38) 
Cough daily, % 16.7 (917) 21.6 (183) 31.0 (342) 49.2 (102) 
BMI (kg/m2) 27.3 ± 4.1 25.5 ± 3.7 26.2 ± 4.2 26.1 ± 4.2 
Current smoking, % 18.0 (1582) 29.6 (308) 41.7 (501) 47.2 (119) 
Former smoking, % 42.7 (3784) 47.7 (499) 42.2 (518) 39.7 (100) 
Pack years current smokers 19.7 ± 12.6 21.5 ± 12.7 23.5 ± 14.8 26.0 ± 16.1 
Pack years former smokers 12.7 ± 12.6 16.6 ± 15.9 19.5 ± 15.9 27.7 ±18.3 
History of Cancer, % 7.7  (616) 10.5 (118) 10.0 (145) 13.9 (38) 
History of CVD, % 13.6 (1092) 16.5 (185) 24.4 (354) 28.2 (77) 
Diabetes, %  5.3 (307) 3.76 (34) 5.1 (59) 6.2 (14) 
Values are mean ± 1 standard deviation, or percentages with absolute numbers in parentheses. 
COPD stadium III and IV are combined together. 
§Dyspnea when walking calmly. 
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Table 2.  Characteristics of the venous thromboembolism (VTE) events                                                                                         
(n = 215) that occurred during follow-up. The Tromsø study 2001–2011.  
 % (n)  
Men 47.3 (101) 
Deep vein thrombosis 49.5 (106) 
Pulmonary embolism 50.5 (109) 
Unprovoked events 37.2 (79) 
  
Clinical risk factors :  
Oestrogen*† 1.9 (4) 
Pregnancy/puerperium† 0 (0) 
Heredity‡ 1.9 (4) 
Other medical conditions§ 17.3 (37) 
  
Provoking factors :  
Surgery 16.4 (35) 
Trauma 8.4 (18) 
Acute medical conditions 17.1 (37) 
Cancer 30.9 (68) 
Immobilityll 18.4 (42) 
Other¶ 6.9 (15) 
  
* Current use of oestrogens or oral contraceptives. 
† Proportion of women. 
‡ VTE in first degree relative aged less than 60 years. 
§ Myocardial infarction, ischemic stroke, heart failure, chronic obstructive pulmonary disease, 
myeloproliferative disorders, inflammatory bowel disease and chronic infections within the 
last year. 
|| Bed rest > 3days last 14 days, confinement to wheelchair, long time travel  with car, boat, 
train or by air  >4 hours within last 14 days, or other type of immobilization. 













Table 3 Incidence rates (IR) and hazard ratios (HR) with 95% confidence intervals (CI) for 
total, unprovoked and secondary venous thromboembolism (VTE) by stages of chronic 
obstructive pulmonary disease (COPD). 
COPD stage Person-years VTE IR
 (95% CI)* HR (95% CI)µ HR (95% CI)§ 
ALL VTE      
Normal 41744 137 3.3 (2.8-3.9) 1 (reference) 1 (reference) 
Stage I 5912 26 4.4 (3.0-6.3) 0.98 (0.64-1.50) 1.02 (0.66-1.57) 
Stage II 8008 40 5.0 (3.7-6.8) 1.09 (0.76-1.56) 1.12 (0.78-1.62) 
Stage III/IV 1526 12 7.9 (4.5-13.8) 1.61 (0.90-2.93) 1.60 (0.88-2.92) 
p for trend    0.2 0.2 
 
UNPROVOKED VTE     
Normal 41744 55 1.3 (1.0-1.7) 1 (reference) 1 (reference) 
Stages I 5912 6 1.0 (0.5-2.3) 0.55 (0.24-1.29) 0.62 (0.26-1.46) 
Stage II 8008 15 1.9 (1.1-3.1) 1.00 (0.56-1.78) 1.07 (0.59-1.95) 
Stage III/IV 1526 3 2.0 (0.6-6.1) 0.99 (0.31-3.25) 1.04 (0.32-3.39) 
p for trend    0.8 1.0 
      
SECONDARY VTE     
Normal 41744 82 2.0 (1.6-2.4) 1 (reference) 1 (reference) 
Stage I 5912 20 3.4 (2.2-5.2) 1.28 (0.78-2.10) 1.27 (0.76-2.12) 
Stage II 8008 25 3.1 (2.1-4.6) 1.16 (0.73-1.82) 1.14 (0.72-1.83) 
Stage III/IV 1526 9 5.9 (3.1-11.3) 2.05 (1.02-4.10) 1.97 (0.97-3.99) 
p for trend    0.1 0.1 
 
    Provoked       
    Normal 41744 39 0.9 (0.7-1.3) 1 (reference) 1 (reference) 
    Stage I 5912 12 2.0 (1.0-3.4) 1.39 (0.71-2.74) 1.53 (0.76-3.06) 
    Stage II 8008 14 1.7 (1.0-3.0) 1.27 (0.68-2.35) 1.25 (0.66-2.37) 
    Stage III/IV 1526 4 2.6 (1.0-7.0) 1.77 (0.63-5.00) 1.71 (0.60-4.88) 
    p for trend    0.2 0.3 
 
    Cancer-related     
    Normal 41744 43 1.0 (0.8-1.4) 1 (reference) 1 (reference) 
    Stage I 5912 8 1.4 (0.7-2.7) 1.05 (0.49-2.25) 1.04 (0.49-2.25) 
    Stage II 8008 11 1.4 (0.8-2.5) 1.03 (0.53-2.03) 1.04 (0.52-2.07) 
    Stage III/IV 1526 5 3.3 (1.4-7.9) 2.33 (0.91-5.95) 2.28 (0.88-5.91) 
    p for trend    0.3 0.3 
      
PE      
Normal 41744 68 1.6 (1.3-2.1) 1 (reference) 1 (reference) 
Stage I 5912 15 2.5 (1.5-4.2) 1.12 (0.64-1.96) 1.21 (0.68-2.14) 
Stage II 8008 19 2.4 (1.5-3.7) 1.01 (0.60-1.69) 1.01 (0.60-1.72) 
Stage III/IV 1526 7 4.6 (2.2-9.6) 1.83 (0.83-4.02) 1.80 (0.81-3.99) 
p for trend    0.4 0.4 
      
DVT      
Normal 41744 69 1.7 (1.3-2.1) 1 (reference) 1 (reference) 
Stage I 5912 11 1.9 (1.0-3.4) 0.84 (0.44-1.60) 0.82 (0.41-1.61) 
Stage II 8008 21 2.6 (1.7-4.0) 1.18 (0.72-1.93) 1.22 (0.73-2.04) 
Stage III/IV 1526 5 3.3 (1.4-7.9) 1.38 (0.55-3.45) 1.39 (0.55-3.51) 
p for trend    0.5 0.4 
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* Per 1000 person-years,  
µ Age was timescale. Adjusted for sex 
§ Adjusted for age, sex, current smoking, body mass index and self-reported cardiovascular diseases (myocardial 
infarction, angina, stroke). 
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Table 4. Mortality rates (MR) per 100 person-years and hazard ratios (HR) with 95% confidence intervals (CI) of death according to stages of 
chronic obstructive pulmonary disease (COPD) and venous thromboembolism (VTE) status 
COPD VTE Person-years Deaths MR (95% CI) HR (95% CI)* HR (95% CI)* 
Yes No 15654 431 2.8 (2.5-3.0) 1.00 (reference)  
Yes Yes 194 41 21.2 (15.6-28.7) 5.54 (4.01-7.66)  
       
COPD-stage       
I No 5947 118 2.0 (1.7-2.4) 1.00 (reference) 1.00 (reference) 
I Yes 70 12 17.1 (9.7-30.1) 7.02 (3.83-12.85) 7.45 (4.10-13.5) 
II No 8170 227 2.8 (2.4-3.2) 1.00 (reference) 1.37 (1.09-1.72) 
II Yes 104 19 18.3 (11.7-28.7) 4.18 (2.60-6.73) 5.57 (3.41-9.09) 
III/IV No 1537 86 5.6 (4.5-6.9) 1.00 (reference) 2.54 (1.92-3.36) 
III/IV Yes 20 10 50.2 (27.0-93.3) 10.88 (5.26-22.52) 24.60 (12.73-47.55) 
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